Ryan Allway | Investerms.com

Abattis Signs LOI With Kanabé to Provide a Full Suite of Downstream Cannabis Solutions to Their Premium Health and Wellness Products

Written by Ryan Allway on Mar 08, 2018

VANCOUVER, British Columbia, March 8, 2018 /PRNewswire/ — Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE: ATT) (OTC: ATTBF) is pleased to announce it has signed a letter of intent (the “LOI“) with Kanabé Corp. (“Kanabé“) to provide Kanabé with cannabinoids as well as formulation, manufacturing, analytical and regulatory services to support the development and commercialization of Kanabé’s products. Kanabé is a Calgary-based manufacturer of various health and wellness products, including topicals, sublingual oils and other skin-care products. Pursuant to the LOI, Abattis and Kanabé have agreed to negotiate in good faith the terms of a definitive research services agreement respecting the terms of their partnership.

“We hope our partnership with Kanabé will enable it to scale its manufacturing capacity, allowing it to enter new retail distribution channels, including storefronts throughout Canada and online stores. Kanabé’s product line will focus on the adult-use market and will be based on Abattis’s downstream cannabis solutions, resulting in a premium product and unparalleled customer experience”, stated Rob Abenante, President and CEO of Abattis. “This is the latest example of our fully-integrated suite of services supporting manufacturers of cannabis- and hemp-infused products from formulation to distribution”, added Mr. Abenante.

“Kanabé believes this partnership will enhance our formulations, with access to Abattis’s full range of services and industry leading technologies, and result in premium quality products. Concurrently with our work with Abattis, we are working to secure distribution agreements for our line of health and wellness products with major retail chains, one of which has 100+ locations throughout various provinces. We are also poised and well situated to provide our products in distribution channels overseen by provincial commissions”, stated Daniel Laferriere, CEO and founder of Kanabé Corp.

“Innovation and compliance are key drivers of our strategy to support the nascent legal market for cannabis and hemp products. For example, Kanabé’s line of high-end health and wellness products could be an ideal use case for our nanotechnology-based delivery platform currently in development,” added Dr. David Galvez, Senior Science Advisor at Abattis.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com

ON BEHALF OF THE BOARD OF

ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante“

Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

View original content:http://www.prnewswire.com/news-releases/abattis-signs-loi-with-kanabe-to-provide-a-full-suite-of-downstream-cannabis-solutions-to-their-premium-health-and-wellness-products-300610657.html

SOURCE Abattis Bioceuticals Corp

Source: PR Newswire (March 8, 2018 – 7:43 AM EST)

The post Abattis Signs LOI With Kanabé to Provide a Full Suite of Downstream Cannabis Solutions to Their Premium Health and Wellness Products appeared first on CannabisFN.

Delta 9 Cannabis Secures Rare Manitoba Conditional Approval

Written by Ryan Allway on Mar 07, 2018

Canada’s cannabis industry is projected to reach up to C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of recreational adult-use cannabis later this year. While the federal government finalizes the legislation, individual provinces have also been working out how they will handle the cultivation, distribution, and sale of cannabis. These rules have created several opportunities among publicly-traded companies in the space.

Delta 9 Cannabis Inc. (TSX-V: NINE) is one licensed producer that could benefit from these new provincial rules. As one of just four groups conditionally approved in Manitoba, the company is uniquely positioned to capitalize on a market that management believes could be worth between $300 million and $500 million per year. Investors may want to take a closer look at the stock given the company’s new conditional approval and partnership with an industry leader.

Manitoba Decides on Four LPs

Manitoba has conditionally approved four groups that will operate the province’s cannabis retail after receiving over one hundred applications. Each of the four groups submitted proposals that met the criteria outlined in the government’s RFP, but official acceptance of the proposals is conditional on them reaching all of the necessary agreements and providing the required documents that were outlined in the government’s RFP.

The four groups that were conditionally approved include:

Delta 9 Cannabis and Canopy Growth Corp. (TSX: WEED)
National Access Cannabis and Manitoba First Nations
Tokyo Smoke and B.O.B. Headquarters
Avana Canada, Fisher River Cree Nation, Chippewas of the Thames of Ontario, MediPharm Labs, and Native Roots Dispensary (a U.S. retailer)

The group applications were evaluated by an independent third party to ensure that the process was fair and equitable. Over the coming weeks, the Manitoba government will work with these groups on the next stages of due diligence, including the number of locations and retail stores each group will be permitted to operate under provincial licensing agreements.

Delta 9’s Agreement with Canopy

Delta 9 Cannabis and Canopy Growth teamed up to build and operate a chain of retail stores throughout Manitoba. The first location has already been built in the Osborne Village area of Winnipeg and has been operating for several months as a resource center and clinic. In addition, the agreement calls for Delta 9’s products to be distributed through Canopy Growth outlets in other provinces and through its Tweed Main Street online sales portal.

“It is hard to overstate how important this award is for our company, our shareholders, and the future of the legal cannabis industry in Manitoba,” said Delta 9 Cannabis CEO John Arbuthnot in a recent press release. “As the only Manitoba producer licensed to sell cannabis, and partnered with the world’s largest cannabis company, we feel we are uniquely situated to serve the Manitoba market with both quantity and quality of product.”

Management estimates that Manitoba’s cannabis market could be worth between $300 million and $500 million per year. In addition to leveraging Canopy Growth’s significant scale, the company also continues to advance its own construction project that’s coming in under budget. Management believes that it is fully funded to build 600 of its self-designed “grow pods”, which could increase its cannabis production to 17,500 kilograms per year.

Looking Ahead

Delta 9 Cannabis Inc. (TSX-V: NINE) is one of just four groups approved to open retail locations in Manitoba’s market, which management believes could be worth $300 million to $500 million per year. Through its partnership with Canopy Growth, the company is uniquely positioned to scale up in the new recreational adult-use market while simultaneously building up its own production capacity using its innovative grow pods.

For more information, visit the company’s website at www.delta9.ca.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please see our disclaimer below and follow the link to view our full disclosure outlining compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Delta 9 Cannabis Secures Rare Manitoba Conditional Approval appeared first on CannabisFN.

Future Farm Tech: A Portfolio Approach To Burgeoning Cannabis Industry

Written by Ryan Allway on

The nascent cannabis industry is poised to exceed $50 billion in annual revenue over the coming years, according to Cowen & Co., driven by the legalization of adult-use cannabis across several states. In Canada, Deloitte believes that the market could exceed C$22.6 billion following the legalization of adult-use cannabis nationwide. Investors have many options when investing in the market, ranging from licensed producers to ancillary service providers.

Future Farm Technologies Inc. (CSE: FFT) (OTCQB: FFRMF) recently moved to uplist to the OTCQX exchange following its joint venture with TCG Investments to acquire an economic interest in five Puerto Rico-based medical dispensary licenses and its acquisition of three licenses from the State of Maine for the cultivation of industrial hemp. These developments translate to a highly transparent company with exposure to both cannabis and hemp markets.

Uplisting to the OTCQX

Future Farm recently announced that its board of directors approved its application to uplist from the OTCQB to the OTCQX International, the Premier Tier of the OTC Markets. At the same time, the company engaged a sponsoring brokerage and counsel to serve as its Designated Advisor for Disclosure to meet the listing requirements. These actions should help increase transparency for investors.

“Uplisting to the OTCQX is an activity we have planned as part of our corporate strategy for some time,” said Future Farm CEO Bill Gildea in the press release announcing the uplisting. “We are confident that the wider visibility amongst the investment community with strengthen stockholder value and enable us to continue on the path of accomplishing our corporate goals.”

Many investors have limitations when it comes to investing in over-the-counter companies. In particular, many institutional investors are unable to invest in companies that have limited disclosure requirements. An OTCQX International listing could open the door to these investors and help broaden the company’s shareholder base.

Finally, the move could set the stage for a future uplisting to a national exchange like the NYSE or NASDAQ. While there are few cannabis companies listed on these exchanges at the moment, possibly due to the federal prohibition of cannabis, future changes to the regulatory environment could open up the door. Companies that are already adhering to OTCQX International standards could have an easier time meeting the more stringent requirements.

A Portfolio Based Approach

Future Farm Technologies recently announced that it closed on its previously announced joint venture with TGC Investments LLC, which owns the Clinica Verde brand of medical cannabis dispensaries in Puerto Rico. Future Farm announced on March 7th that it has signed the first of five leases for their Clinica Verde branded Puerto Rico dispensaries. The company expects to sign two more leases in the next thirty days with the additional two leases to follow soon after.

Puerto Rico has legalized medical marijuana for over a dozen medical conditions, including Alzheimer’s, cancer, Lou Gehrig’s disease, Parkinson’s disease, rheumatoid arthritis, Crohn’s disease, epilepsy, and others. In October 2017, the government approved a rule that would enable patients to go to any open clinic, regardless of the dispensary that they had been assigned, which opens the door to new cannabis dispensaries.

In addition to cannabis, the company recently announced that it received three licenses from the State of Maine for the cultivation of industrial hemp. The move comes shortly after the company signed a lease for an initial 12,960 sq. ft. grow area in a 60,000 sq. ft. building with an option to expand or purchase the building. Management plans to germinate 250,000 hemp seeds over the next few months and has the option to expand from 100 to 1,000 acres.

The company’s focus is on cultivating feminized seeds that contain 0.03% of less THC while averaging 15% CBD content. Once harvested, the hemp will be dried and refined using the company’s high output oil processing equipment, creating both CBD oil and high value isolate for making edibles, creams, and lotions. Management believes that the market for CBD is poised to rapidly expand following the FDA’s decision on GW Pharma’s Epidiolex®.

In addition to these retail and hemp projects, the company is ramping up its cannabis assets. The company purchased a building in Rhode Island to cultivate and sell cannabis, as well as an operating greenhouse in Florida that’s generating $3 million in revenue and $500 in EBITDA while it applies for its cannabis license in the state. Management also signed a letter of intent to purchase a 51% stake in Attleboro Massachusetts to cultivate and sell cannabis.

Finally, the company formed a joint venture with Israeli Agriscience, a leader in the development of cannabis clones in Canada and California, to provide exposure to the research and development side of the industry.

Looking Ahead

Future Farm Technologies Inc. (CSE: FFT) (OTCQB: FFRMF) represents a compelling investment opportunity in the burgeoning cannabis industry. After deciding to uplist to the OTCQX, the company plans to offer investors greater transparency in a bid to broaden its shareholder base and ultimately generate greater shareholder value. At the same time, the company’s dual focus on cannabis and hemp positions it to take advantage of both areas of the rapidly growing cannabis industry.

For more information, visit the company’s website at www.futurefarmtech.com.

Disclaimer

The post Future Farm Tech: A Portfolio Approach To Burgeoning Cannabis Industry appeared first on CannabisFN.

NanoSphere Health Sciences’ Cannabis Brand Now Available in Over 100 Dispensaries in Colorado

Written by Ryan Allway on

Evolve Formulas’ Transdermal NanoSerum™ Continues to Expand

DENVER (March 7, 2018) – NanoSphere Health Sciences Inc. (CSE: NSHS/ OTC: NSHSF) cannabis product brand Evolve Formulas is now stocked in over 100 dispensaries throughout Colorado. The company’s pioneering product, Transdermal NanoSerum™, uses the NanoSphere Delivery System™ developed by the biotechnology firm to allow cannabis to enter systemic circulation within ten minutes for fast-acting, effective relief from pain, inflammation and anxiety. This milestone comes on the back of continuous growth, with the company recently signing a licensing agreement in California.

“Evolve Formulas, using revolutionary nanotechnology developed by NanoSphere Health Sciences, is advancing the cannabis industry,” said David Sutton, COO and President of Nanosphere Health Sciences. “Evolve Formulas products are now available in over 100 dispensaries throughout Colorado and will launch in California Summer 2018. NanoSphere Health Sciences will continue to expand and bring these products into new markets and is currently in negotiations with several potential partners nationally and internationally.”

The patent-pending NanoSphere Delivery System™ is the only nanotechnology being applied to the cannabis industry that can transport THC directly into the bloodstream and to the CB1 and CB2 receptors of the endocannabinoid system. The delivery system offers precise, measurable doses and rapid absorption. Using this industry-first technology, cannabinoid molecules in NanoSerum™ are encapsulated in nano-sized lipid membranes, enabling them to pass through the skin into the bloodstream and cells, increasing bioavailability and bioactivity.

NanoSerum™ is now available in 5ml and 10ml pen sizes in select medical and recreational dispensaries. For a full list of store locations or more information, please visit https://www.evolveformulas.com/store-locator/. The NanoSerum™ formula is 100 percent natural and 100 percent free of contaminants, made from natural biocompatible, biodegradable non-toxic materials.

For more information or to schedule an interview, please contact Emily Kielthy at media@nanospherehealth.com or 646-695-7045.

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visithttp://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world’s first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patent-pending NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us onFacebook, Instagram and Twitter.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution
This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

The post NanoSphere Health Sciences’ Cannabis Brand Now Available in Over 100 Dispensaries in Colorado appeared first on CannabisFN.

Choom™ Announces First Regional Retail Investment Group

Written by Ryan Allway on

VANCOUVER, March 7, 2018 /CNW/ – Choom™ (CSE: CHOO; OTCQB: CHOOF) is pleased to announce that it has signed the first agreement in its retail investor program and is pleased to welcome an Okanagan consortium to the Choom™ brand. This follows Choom’s announcement on January 18^th, 2018 highlighting a retail strategy of developing a chain of branded retail cannabis dispensaries across Canada.

Choom Holdings Inc. (CNW Group/Choom Holdings Inc.)

The consortium, known as the ‘Thompson Okanagan Choom Group’ (“TOCG”) has secured the exclusive territory rights to open multiple Choom™ branded retail dispensaries in the Thompson-Okanagan region. TOCG is comprised of local investors and business partners led by Debra G Adams, Sherman Dahl, Imre Kovacs and Kent Adams, combining to bring decades of business experience to contribute to the success of Choom™ locations in the Thompson-Okanagan region.

Debra G. Adams, RN – Managing Partner & Business Development
Mrs. Adams recently retired from a 30-year career as community registered nurse to seek opportunity in the cannabis sector with the TOCG. Mrs. Adams believes the retail opportunities for the recreational market will dwarf the medicinal space. “We’ve been closely monitoring the explosion of Cannabis companies in Canada and are very pleased to be working with a ‘best in class’ operator such as Choom™, states Mrs. Adams. The branding, professionalism and style of Choom™ is second to none and our team can’t wait to get started”!

Sherman Dahl – VP Finance
Mr. Dahl is a seasoned investor and financier who is well versed in finance and marketing strategies for small cap private and public Canadian companies. Mr. Dahl has expertise in identifying undervalued companies and introducing these opportunities to his buy-side network of clients, strategic co-investors and marketing participants. Mr. Dahl has a proven record of being able to raise capital and increase investor awareness and liquidity. Mr. Dahl was previously a vice-president and investment adviser with National Bank Financial, a leading Canadian investment dealer. In addition to managing a $150-million retail book and achieving Chairman’s Council level, Mr. Dahl participated in numerous capital raises totaling over $100-million directly for various issuers with total issuer financings of $1 billion on behalf of retail and institutional clients over a 20-year career. Pretium Communications is an advisory and consulting firm based in Vernon, B.C. Pretium Holdings also owns and operates restaurants and media print businesses in Vernon, B.C. Mr. Dahl holds a Bachelor of Business Administration (Economic and Finance Major) degree from the University of Regina.

Imre Kovacs – Special Advisor
A seasoned entrepreneur who founded his first company while attending university and after ten successful years, entered the emerging legalized cannabis market. Imre operated Canada’s first municipally-licensed dispensary in Vernon, BC, setting the blueprint for other dispensaries to follow. His expertise and experience create a unique inside perspective that will be invaluable in assisting to create successful retail operators.

Kent Adams – VP Marketing
Mr. Adams’ experience in sales & marketing dates back over 25 years. By combining an early passion for technology with his comprehension of powerful digital advertising platforms, Mr. Adams has leveraged previous experience to develop strategies and implementations that have resulted in very successful digital campaigns.
“It’s very exciting to be welcomed into the Choom™ family and to anticipate the spectacular opportunities that lay ahead in this high growth sector. We’ve been patiently considering opportunities and we feel this is the right time, and the right company with which to enter into the space.”

“We’re inviting people to join a world class brand built exclusively for the recreational cannabis market and we’re encouraging them to join us by registering for their own Choom^TM Store in the Thompson Okanagan region,” states Mrs. Adams. Choom™ is using design and retail strategies that have worked successfully at some of the most profitable storefronts in the country. We are telling our Choom story with our stores and will elevate the concept of a high-quality product though our new retail environments, and we’re inviting others to join us.

With an estimated $4.9B to $8.7B¹ retail market coming, now is the right time get involved in this rapidly expanding industry. Choom™ is very pleased to start welcoming dispensary entrepreneurs to the Choom™ brand. As we move forward in the design process and developing our retail strategy, adding passionate people will be key to growth. In an industry where dispensaries in a legal recreation market are making more revenue per square foot than Whole Foods² we look forward to adding people who want to get in on the ground floor. Here’s to good times with good friends.

To view the Choom concept store please click on the link attached: www.choom.ca/retail

SAY HELLO TO CHOOM^™Choom™ was created for and inspired by the Choom Gang; a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom”. Now, after four decades, Choom™ is bringing the spirit of Hawaii to Canada. We’re planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb. Choom™ will provide an amazing experience for customers, and bring style, sophistication and fun to the cannabis market with through our Choom™ stores.

“Chris Bogart”
President & CEO

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking information
This news release contains forward-looking information relating to the Company’s proposed activities and other statements that are not historical facts. Forward-looking information relates to management’s future outlook and anticipated events or results, and include statements or information regarding the future plans or prospects of the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with the results of diligence investigations, developments in the cannabis sector, delays resulting from or inability to obtain required regulatory approvals and ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company’s interim and most recent annual financial statement or other reports and filings, including the Company’s Listing Statement, made with the applicable Canadian securities regulators. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.

1.	Deloitte, Recreational Marijuana – Insights and Opportunities Report https://www2.deloitte.com/content/dam/Deloitte/ca/Documents/Analytics/ca-en-analytics-DELOITTE%20Recreational%20Marijuana%20POV%20-%20ENGLISH%20FINAL_AODA.pdf
2.	http://time.com/money/4385243/pot-shops-whole-foods-sales/

SOURCE Choom Holdings Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/March2018/07/c2871.html

Choom Holdings Inc., Chris Bogart, President & CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.caCopyright CNW Group 2018

The post Choom™ Announces First Regional Retail Investment Group appeared first on CannabisFN.

Future Farm Signs Dispensary Lease for High Traffic Puerto Rico Location

Written by Ryan Allway on

VANCOUVER, British Columbia, March 7, 2018 /PRNewswire/ —

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (CSE: FFT.CN) (OTCQX: FFRMF), which has built a portfolio of projects across the United States and the Commonwealth of Puerto Rico, is pleased to announce that its Puerto Rico subsidiary has signed the first of five planned leases for its Clinica Verde branded Puerto Rico dispensaries. The Company expects to sign two more leases in the next thirty days with the additional two leases to follow soon after.

The Future Farm Clinica Verde branded dispensary is located in the Condado neighborhood of San Juan, one of the island’s most highly trafficked areas.

“Now that we have identified a prime dispensary location and signed a lease we are excited to work on the build out,” comments William Gildea, Chairman and CEO of Future Farm. “We look forward to providing clean cannabis to the island’s patients and generating sales.”

Future Farm continues to execute on its strategy of building a portfolio of valuable, revenue-generating assets in the fastest growing cannabis and hemp markets in North America. Mr. Gildea continues, “I look forward to building out and adding to our existing portfolio, which has grown quickly over the past year with assets in Rhode Island, Maine, California and Florida.”

On behalf of the Board,

Future Farm Technologies Inc.
William Gildea, Chairman & CEO

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land. The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability. The Company also utilizes a leading cannabis oil extraction technology, which enables the Company to process 20lbs/hour of cannabis plant to yield approximately 908 grams/hour of oil.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com, which caters to B2B customers, is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com, which caters to both large and small agriculture green houses and controlled cultivation centers.

The Company recently acquired the exclusive right to use a patented, augmented reality (AR) technology in the cannabis industry. As described in more detail above, the Company has decided to spin this asset off to its shareholders.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

For further information, contact
William Gildea
Director
+1-617-834-9467

SOURCE Future Farm Technologies Inc.

The post Future Farm Signs Dispensary Lease for High Traffic Puerto Rico Location appeared first on CannabisFN.

Micron Waste Accelerates Development of Cannabis Waste Digester

Written by Ryan Allway on Mar 06, 2018

The cannabis industry is projected to reach $50 billion in annual revenue over the coming years, according to Cowen & Co., driven by the legalization of adult-use cannabis across several states. At the same time, the Canadian cannabis industry is expected to reach C$22.6 billion in size, according to Cowen & Co., driven by nationwide legalization. The rapid growth, however, has led to some important growing pains that must be addressed.

Micron Waste Technologies Inc. (CSE: MWM) (OTC: MICWF) addresses a critical issue that faces the cannabis industry – organic waste disposal. With plans to accelerate its commercialization, investors may want to take a closer look at the company as it prepares to install an initial unit with Aurora Cannabis Inc. (TSE: ACB) before targeting the wider market.

The Cannabis Waste Problem

The cannabis industry may have been founded on the principles of peace and love, but the industrialization of the sector has taken an entirely new direction. In particular, industrial cannabis cultivation has taken a significant toll on the environment in terms of both energy use and waste disposal. The growth of the industry is rapidly amplifying these problems and creating a need for more sustainable solutions for the long-term.

The most prominent environmental concern is the cannabis industry’s tremendous use of electricity. According to Denver’s Department of Public Health and Environment, the cannabis industry consumes nearly four percent of the city’s total electricity. Marijuana’s share of the energy mix is also growing at a much faster rate than overall energy use. These trends are concerning as many other states move to legalize adult-use cannabis.

A lesser known problem involves the organic waste produced by cultivation operations. Most organic waste produced by the industry ends up in landfills since they’re the most cost-effective disposal option. In addition to taking up space in a landfill, organic waste undergoes anaerobic decomposition in a landfill, due to the lack of oxygen, and generates methane gas. These gases are 25 times more potent greenhouse gases than carbon dioxide!

Micron’s Innovative Solution

Micron Waste’s aerobic digestion and treatment technology converts organic waste into clean water that meets municipal effluent discharge standards. By leveraging micro-oxygen cubicles, the technology enhances the digestion efficiency of microorganisms by up to 95 percent, with the remaining five percent of undigested particles undergoing further treatment. These technologies have already been proven in the food service industry.

In December, the company announced a strategic partnership with Aurora Cannabis, one of the largest licensed producers of medical marijuana under Canada’s ACMPR program. The partnership calls for preliminary research and the placement of initial units at Aurora Cannabis’ cultivation facilities in the second quarter of 2018. These placements should provide a key proof-of-concept for sales to the wider industry with Aurora leading the way.

Accelerating Development

Micron Waste recently announced the engagement of BC Research Inc., a renowned engineering consultancy, to accelerate the commercialization of its waste digester technology for the cannabis industry. Under the terms of the agreement, BC Research will deliver a unit that functions in a broad range of temperatures, making it suitable for deployment on a global scale in a wide range of climates, while also making the units suitable for mass production.

“We are extremely pleased to be working with BC Research and Aurora Cannabis to develop a market-ready Micron Cannabis Waste Digester,” said CEO Rav Mlait. “The enhanced features requested by our clients are anticipated to accelerate commercial adoption and make Micron’s technology more attractive to cannabis producers seeking a less costly, more convenient, and ‘greener’ means of handling organic waste.”

BC Research is a global provider of engineering and equipment packages to the chemical, pulp, paper, minerals processing, and electrochemical sectors. With a staff of over 200 professionals, the company has completed capital project on five continents and has become a recognized worldwide leader in nitration, sulfuric acid, and electrochemistry. The company also provides support to early-stage companies looking for engineering design and fabrication support.

Looking Ahead

Micron Waste Technologies Inc. (CSE: MWM) (OTC: MICWF) offers investors an alternative investment in a business that will serve the budding cultivation sector as companies greatly increase production levels in advance of Canada’s adult-use legalization. With plans to accelerate the development of its breakthrough technology, and a deal in place with one of the largest licensed producers in Canada, the company is well positioned to commercialize its technology over the near-term.

For more information, visit the company’s website at www.micronwaste.com.

Disclaimer

The post Micron Waste Accelerates Development of Cannabis Waste Digester appeared first on CannabisFN.

Ehave Solutions Gain Traction in Cannabis Industry

Written by Ryan Allway on

The cannabis industry is expected to reach $50 billion by 2022 in the U.S. alone, according to Cowen & Co., driven by a growing number of states that have legalized the drug for medical and adult use. At the same time, a growing number of researchers have become interested in the drug as a potential treatment for a wide range of medical conditions. The problem is that its difficult to keep effective records in cannabis clinical trials.

Ehave Inc.’s (OTCQB: EHVVF) Connect platform is an innovative bioinformatics tool that enables researchers, physicians, and patients to connect in a way that was never before possible. By bringing all of these parties together, everyone can work towards the common goal of improving patient outcomes on a highly personalized level.

Revive Therapeutics Collaboration

Ehave recently announced a collaboration agreement with Revive Therapeutics Ltd. (TSX-V: RVV) (OTCQB: RVVTF) to provide enhanced patient and clinical research data management. Under the terms of the agreement, Revive will integrate the Ehave Connect platform with its ongoing research involving the use of medical cannabis for the treatment of liver diseases, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and fibrosis.

The Ehave Connect platform collects and integrates patient data from clinical systems, licensed health surveys, and patient and clinician reported outcomes. By keeping patients engaged throughout the healthcare journey, the platform helps connect teams across disciplines and ensure that patients have the best treatments and options available to them.

“Our collaboration with Revive is an important step toward realizing Ehave’s broader goal of partnering with the healthcare community, and in particular, companies advancing novel medical cannabis products, to facilitate clinical trials and patient management with a single easy-to-use, end-to-end data informatics platform,” said Ehave CEO Prateek Dwivedi.

Aequus Pharma’s Clinical Trials

Ehave announced a collaboration with Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) just a week after its agreement with Revive. Under that agreement, Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying cannabinoid-rich formulations for treating a number of neurological disorders.

“Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original letter of intent with Ehave,” said Aequus CEO Doug Janzen. “We have a number of different clinical trials in late-stage planning and see multiple opportunities for us to leverage our traditional pharmaceutical expertise in designing and implementing clinical programs [in the cannabis space].”

The agreement involves Aequus paying Ehave a per-patient fee for trials conducted using its Ehave Connect platform. In return, Aequus will receive patient assessment, diagnostic, and therapeutic outcomes and side-effect profile content from formal and informal studies conducted using the platform. Aequus will also fully own all clinical results and data generated from trials using the Ehave Connect platform.

“Our robust bioinformatics platform allows us to provide customized, next generation clinical solutions that empower pharmaceutical developers such as Aequus to be successful,” said Ehave CEO Prateek Dwivedi. “We look forward to helping them advance their clinical programs and potentially improve outcomes for patients with neurological disorders who may benefit from Aequus’ products.”

Looking Ahead

Ehave Inc. (OTCQB: EHVVF) represents a compelling investment opportunity in the pharmaceutical and cannabis industries. With two new partnerships in March, the company has demonstrated its ability to execute its plan to become a leading platform for the research and development of cannabinoid therapeutics. Investors may want to take a closer look at the stock as it ramps up its commercialization with these new license agreements.

For more information, visit the company’s website at www.ehave.com.

Disclaimer

The post Ehave Solutions Gain Traction in Cannabis Industry appeared first on CannabisFN.

Emerald Health Ramps Up World Class Cultivation Facility in B.C.

Written by Ryan Allway on

The Canadian cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis on a national level. While most licensed producers are independently scaling their production capacity and maneuvering through the learning curve of growing cannabis in large scale, others have partnered with existing agricultural giants to quickly scale up operations in a way that avoids many of the growing pains that they would otherwise face.

Emerald Health Therapeutics Inc.’s (TSX-V: EMH) (OTCQX: EMHTF) partnership with Village Farms International (TSX: VFF) (OTCQX: VFFIF) is a great example of the latter. With over 30 years of agricultural experience, and existing facilities well-suited to convert into cannabis cultivation facilities, the company was a natural choice for a licensed producer to partner with and become one of the largest licensed producers in the country.

Securing a Cultivation License

Emerald Health and Village Farms recently announced that Health Canada issued a cultivation license for the co-owned Delta 3 greenhouse operation under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

“Our joint venture is well positioned to be a leading supplier in the imminent legal adult-use Canadian cannabis market, with potentially significant benefit to each of our companies and shareholders,” said Emerald Health Executive Chairman Avtar Dhillon, MD, in a recent press release announcing the joint venture’s new cultivation license.

The 1.1 million sq. ft. cannabis growing facility is located in Delta, British Columbia and is conservatively projected to produce 75,000 kilograms of high quality cannabis when it moves into full production. By putting cutting-edge technologies and cultivation practices into place, management aims to become one of the lowest cost producers at less than $1.00 per gram, which could make the joint venture one of the most profitable licensed producers.

The conversion of the first 250,000 sq. ft. of the 1.1 million sq. ft. Delta 3 greenhouse is already substantially completed and is expected to come online in April 2018. The remainder of the 1.1 million sq. ft. facility is expected to enter into full production in 2019.

In addition, the joint venture holds options on two additional greenhouses owned by Village Farms that could expand production capacity to 4.8 million sq. ft. – making it potentially one of the biggest licensed producers in the world.

Innovative Technologies in Place

Emerald Health’s joint venture is converting the Delta 3 greenhouse operation to cannabis production with meticulous attention to detail. Growing agricultural crops on a large scale at competitive prices is extremely challenging for any producer, but Village Farms has tremendous experience growing a wide range of agricultural produce over several decades. The joint venture aims to set a new standard in the Canadian cannabis industry.

“With Emerald’s in-depth cannabis expertise, Village Farms’ know-how based on innumerable crop cycles over 30 years of large-scale greenhouse growing, and working with global agricultural leads and high-tech facilities and systems experts, we configured this greenhouse for continuous weekly harvesting year-round, maximizing operating efficiencies, and flexibility to adapt to an evolving market,” said Dr. Dhillon.

The Delta 3 greenhouse features:

Automated growing systems to optimize efficiency;
Industry-leading HVAC systems supported by advanced data technologies;
High tech light deprivation and supplementation systems;
State-of-the-art drying, trimming, and packaging areas;
Proprietary labour tracking systems;
Secure low-cost electricity from BC’s hydroelectric power plants

Looking Ahead

Emerald Health Therapeutics Inc. (TSX-V: EMH) (OTCQX: EMHTF) is strongly positioned in Canada’s rapidly growing cannabis industry. Through its Village Farms partnership, the company has gained access to some of the smartest minds in agriculture and is rapidly scaling up its operations to 250,000 sq. ft. and then to 1.1 million sq. ft. by next year. Combined with its other wholly owned Lower Mainland facility, its extensive life sciences expertise, and its focus on product innovation, investors may want to take a look at the stock as it gears up through 2018.

For more information, visit the company’s website or investor presentation.

Disclaimer

The post Emerald Health Ramps Up World Class Cultivation Facility in B.C. appeared first on CannabisFN.

Tweed To Present A Collaborative Fashion Show at Toronto Men’s Fashion Week Fall/Winter 2018

Written by Ryan Allway on

TORONTO, ON, March 5, 2018 /CNW/ – Tweed Inc. (“Tweed”) is proud to present a collaborative fashion show at TOM* F/W this coming week. Over the past four years, Tweed has grown and sold thousands of kilograms of legal, high-quality cannabis products to medical customers across the country, always staying true to its roots and personality as an approachable, proudly Canadian producer.

On the evening of March 9, 2018, working in collaboration with some of Canada’s top clothing designers, Tweed is set to present its first ever runway show, Tweed: Fabric of Creativity, at Toronto Men’s Fashion Week. The show will feature 36 designs by 18 of Canada’s top talents, and will showcase the Tweed personality to a new, equally discerning audience.

Tweed: Fabric of Creativity will showcase the immense talents of designers Zane Barlas, NICO, Xian, Pascal Labelle, Candace Daniela, Tristan Licud, Nabeel Sheikh, JM Trends, Joseph Tassoni, Shelli Oh, Kristian Nielsen, Thomas Henry, Austen Dor, WRKDEPT, L’MOMO, Get Fresh Company, Ross Mayer, and FARLEY CHATTO.

The designers and their teams have been tasked with creating ensembles that combine both tweed fabric as well as their interpretation of the essence of the Tweed brand for the runway show.

The fashion show is just one component of Tweed’s participation in Toronto Men’s Fashion Week. For the duration of TOM* (March 9 to 11, 2018), as well as its sister event, Toronto Women’s Fashion Week (March 12 to 14, 2018), Tweed will have an on-site informational exhibit so that the adult, fashion community can get to know who we are as Canadian leaders and proud cannabis connoisseurs.

Tweed was founded with the belief that cannabis can be a force for good. Not something that should be hidden, but something which deserves informed, open dialogue. Whether through doctor education, our celebrated Artists in Residence program, or fashion week, Tweed supports the communities in which it is present.

“With brand names like Argyle and Herringbone, we are excited to finally engage with the diverse and creative fashion community to bring our personality to life, enriching the fabric of Tweed through dialogue and engagement,” said Bruce Linton, co-founder and CEO of Tweed. “This is an exciting time and an exciting project for Tweed.”

Tweed: Fabric of Creativity takes place Friday, March 9, 2018 at 9pm during Toronto Men’s Fashion Week at 1 Yonge Street.

About Tweed
Tweed is a wholly owned subsidiary of Canopy Growth Corporation (TSX:WEED) and a globally recognized cannabis production brand. It has built a large and loyal following by focusing on quality products and meaningful customer relationships. Tweed doesn’t just sell cannabis, it facilitates a conversation about a product we’ve all heard about but haven’t met intimately yet. It is approachable and friendly, yet reliable and trusted. As cannabis laws liberalize around the world, Tweed will expand its leading Canadian position around the globe. Learn more at www.tweed.com.

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, its subsidiaries, or its affiliates to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection. The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Canopy Growth Corporation

For further information: interview requests with Tweed`s Director of Marketing Amy Wasserman or any of the 18 featured designers, designer sketches, and hi-res photography, please contact: Brill Communications at 416-533-6425; Desia Halpin-Brill, desia@brillcommunications.ca; Myriam Tardif, myriam@brillcommunications.ca

The post Tweed To Present A Collaborative Fashion Show at Toronto Men’s Fashion Week Fall/Winter 2018 appeared first on CannabisFN.

Pivot Pharma Acquires Thrudermic, LLC

Written by Ryan Allway on

VANCOUVER, British Columbia, March 06, 2018 (GLOBE NEWSWIRE) — via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”) is pleased to announce the acquisition of Thrudermic, LLC (“TDL” or “Thrudermic”), a privately held North Carolina company. Pivot previously announced a licensing agreement with Thrudermic but has decided to exercise its option to acquire 100% of TDL. Pivot will pay $1.00 (USD) for all of the issued and outstanding units of Thrudermic, and issue an aggregate of 500,000 common shares in the capital of Pivot to Dr. Joseph Borovsky and Dr. Leonid Lurya for their intellectual property portfolio, including patents, good will and know-how in connection with the TDL Transdermal Nanotechnology. Dr. Borovsky, has been appointed Pivot’s Vice President, Product Formulation, and Dr. Lurya has been appointed Executive Director, Product Formulation.

The TDL Transdermal Nanotechnology is intended for the formulation and delivery of dosable bio-cannabis products. On behalf of Pivot, Thrudermic recently filed three additional patent applications related to improved formulation and delivery for new routes of administration of cannabinoids and will increase the number of products in the Company’s pipeline.

“Thrudermic is very excited to become part of the Pivot organization. Our lipid-based nano-dispersion technology is well suited for the emerging cannabis industry. Pivot’s goal is to increase cannabinoid bioavailability, drug release rates and improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health and wellness needs,” states Dr. Borovsky.

Dr. Borovsky, formerly the director of research and development for Mead Corporation, received his Bachelor of Science degree in Chemistry from UCLA and his Ph.D. in Physical Organic Chemistry from the University of Massachusetts at Amherst. He also completed a year of post-doctoral research in Medicinal Chemistry at Washington State University College of Pharmacy and was a Research Fellow in Synthetic Organic Chemistry at Harvard University. Dr. Lurya is the inventor of Thrudermic transdermal technology and has authored several patents. He received his MD from the Moscow Medical Institute No. 2, Russia, and then completed his PhD in Biophysics, Chemical Physics Department at the Weizmann Institute of Science, Israel.

Dr. Patrick Frankham, Pivot’s CEO, comments, “Thrudermic is Pivot’s fourth disruptive formulation and delivery platform for cannabinoids. We are thrilled that Dr. Borovsky and Dr. Lurya have agreed to join us to develop and commercialize therapeutic bio-cannabis products. They are highly experienced formulations experts with many years of pharmaceutical industry know-how. Pivot continues to position itself as a leader in the delivery of dosable bio-cannabis, something that consumers and regulatory agencies will demand as legalization occurs.”

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or Pivot Green Stream), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical); Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. PGS will seek to register these as Natural Health Products (NHP) for consumers. Products following the NHP pathway have shorter development cycles and can generate revenue faster than traditional pharmaceuticals. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or Pivot Green Stream, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact:

Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Source: GlobeNewswire (March 6, 2018 – 9:12 AM EST)

The post Pivot Pharma Acquires Thrudermic, LLC appeared first on CannabisFN.

Abattis Rebrands as a Downstream Solutions Provider for the Cannabis Market

Written by Ryan Allway on

VANCOUVER, British Columbia, March 06, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce it has officially rebranded itself as a one-stop provider of downstream cannabis solutions for licensed producers (“LPs”) and manufacturers of cannabinoid-containing products. The Company’s new focus on downstream solutions reflects several of its recent acquisitions and the success of its fully integrated services offerings. These offerings now include biomass production, federally-licensed research and development and analytical services, regulatory services, logistics support for the manufacture, sale, distribution and marketing of cannabinoid-containing finished products and cannabinoid delivery products and blockchain-based peer-to-peer payment technologies.

“We intend for the rebranding to consolidate our recent acquisitions and pave the way for exciting new partnerships in the future,” stated Rob Abenante, President and CEO of Abattis. “For example, our recent acquisition of Gabriola Green Farms will round out our supply chain, providing us and our partners with integrated services spanning from biomass production to the manufacture of high-end cannabis extracts,” added Mr. Abenante.

“While continuing to develop our in-house nanotechnology delivery platforms, we hope to support our partners in multiple aspects of their businesses, from helping them increase manufacturing and distribution capacity to, in the case of established brands, guiding their entry into the cannabis space. Our suite of integrated services will also address our partners’ future needs, providing comfort that they will be able to adapt once legalization arrives this summer,” further stated Mr. Abenante.

“Abattis’s wide range of downstream services allows it to add value and ensure regulatory compliance for its partners, while assisting the development of their functional foods and beverages, cosmetics, veterinary and over-the-counter health products, to name a few,” added Dr. David Galvez, Senior Science Advisor at Abattis.

Recent Developments

Gabriola Green Farms

On March 2, 2018, the Company announced that it had acquired a 90% ownership interest in Gabriola Green Farms Inc. (“Gabriola Green Farms”), an LP applicant located on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia.

By becoming the majority-shareholder of Gabriola Green Farms, Abattis intends to secure access to cannabis biomass for its extraction and manufacturing activities with respect oils, resins and isolates. These added value products could be used as stand-alone applications or as active ingredients for current and new finished products.

Green Tree Therapeutics

On January 25, 2018, the Company announced that it had acquired Green Tree Therapeutics Corporation (“Green Tree”), the owner of a successful brand of vaporizers sold in more than 130 medical and recreational stores across North America. Green Tree’s products will soon be available through Abattis’s wholly-owned subsidiary Vergence Naturals Ltd. Abattis’s acquisition of Green Tree will allow the Company to directly pair and distribute cannabinoid-containing oils and extracts with Green Tree’s line of vaporizers.

CannaNUMUS

On February 8, 2018, the Company announced that it had acquired a 49% stake in CannaNUMUS Blockchain Inc. (“CannaNUMUS”). Abattis’s investment in CannaNUMUS has already reached two significant milestones by securing an investment agreement with Active Health Products Ltd. and acquiring a 10% stake in Gabriola Green Farms.

With this acquisition, Abattis has gained the ability to offer blockchain-based peer-to-peer payment services to cannabis merchants, a market segment not been currently served by traditional financial institutions. Abattis believes that its investment in CannaNUMUS will appreciate significantly in value as CannaNUMUS gets closer to an ICO (Initial Coin Offering) and enters into agreements with other LPs and late stage LP applicants.

Collaboration with UBC on Nanotechnology

On February 12, 2018 the Company announced the sponsorship of a research study in partnership with Mitacs to explore the development of nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil. The research and development work is being led by scientists from Abattis and the Faculty of Land and Food Systems at the University of British Columbia (“UBC”).

Through this collaboration, Abattis hopes to develop a proprietary technology that could be applied to the manufacture and distribution of high-end nanoemulsified cannabinoid-rich oils with enhanced absorption and bioavailability. These oils could be used to create safe and stable premium foods and beverages and could be used in cosmetics and veterinary applications.

About Abattis Bioceuticals Corp.

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante”
Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the Company’s intention for the rebranding to consolidate its recent acquisitions and pave the way for exciting new partnerships in the future; the Company’s acquisition of Gabriola Green Farms rounding out its supply chain and providing Abattis and its partners with integrated services spanning from biomass production to the manufacture of high-end cannabis extracts; the Company’s hope to support its partners in multiple aspects of their businesses, from helping them increase manufacturing and distribution capacity to, in the case of established brands, guiding their entry into the cannabis space; the Company’s suite of integrated services addressing its partners’ future needs, providing comfort that they will be able to adapt once legalization arrives this summer; Abattis’s intention to secure access to cannabis biomass for its extraction and manufacturing activities with respect oils, resins and isolates; Gabriola Green Farms’s products’ potential use as stand-alone applications or as active ingredients for current and new finished products; Abattis’s belief that its investment in CannaNUMUS will appreciate significantly in value as CannaNUMUS gets closer to an ICO (Initial Coin Offering) and enters into agreements with other LPs and late stage LP applicants; Abattis’s hope to develop a proprietary technology that could be applied to the manufacture and distribution of high-end nanoemulsified cannabinoid-rich oils with enhanced absorption and bioavailability and that such oils could be used to create safe and stable premium foods and beverages and could be used in cosmetics and veterinary applications. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that the rebranding will not consolidate the Company’s recent acquisitions or pave the way for exciting new partnerships in the future; that the Company’s acquisition of Gabriola Green Farms will not round out the Company’s supply chain or provide it or its partners with integrated services spanning from biomass production to the manufacture of high-end cannabis extracts; that the Company will not be able to support its partners in multiple aspects of their businesses; that the Company’s suite of integrated services will not address its partners’ future needs or will not provide comfort that such partners will be able to adapt once legalization arrives this summer; that Abattis will not be able to secure access to cannabis biomass for its extraction and manufacturing activities with respect oils, resins and isolates; that Gabriola Green Farms’s products will not be useful as stand-alone applications or as active ingredients for current or new finished products; that Abattis’s investment in CannaNUMUS will not appreciate as expected or at all, or that CannaNUMUS will not complete an ICO (Initial Coin Offering) or enter into agreements with other LPs or late stage LP applicants; that Abattis will not develop a proprietary technology that could be applied to the manufacture and distribution of high-end nanoemulsified cannabinoid-rich oils with enhanced absorption and bioavailability or that such oils may not be used to create safe and stable premium foods and beverages or may not be used in cosmetics and veterinary applications; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: GlobeNewswire (March 6, 2018 – 8:31 AM EST)

The post Abattis Rebrands as a Downstream Solutions Provider for the Cannabis Market appeared first on CannabisFN.

Friday Night Inc. Closes on Land Purchase Agreement

Written by Ryan Allway on

VANCOUVER, March 6, 2018 /CNW/ – Friday Night Inc. (the Company or Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF) is pleased to announce the closing of its previously announced land purchase agreement.

Friday Night Inc. (CNW Group/Friday Night Inc.)

The Company reports that it has closed on the purchase of an additional 2.78 acres of land which is contiguous to the current location that will host Alternative Medicine Association’s (“AMA”) new cultivation facility. AMA now owns 4.17 acres of land on a major thoroughfare in Las Vegas which includes the original plot of 1.39 acres that has already received a special use permit for cannabis cultivation and a building permit for its future, state-of-the-art 67,000 sq. ft. cultivation facility.

“The additional land will allow for future expansion of the cultivation facility as well as a new production facility when needed. It could also be used as the location for a retail dispensary license application if the Company decides to apply when that window opens again. This acquisition gives us a strategic advantage and flexibility for our long-term plans to meet the market demand as it grows,” said Mark Zobrist, Managing Partner of Alternative Medicine Association.

About Friday Night Inc.

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada as well as an international cannabis and mining security logistics consulting firm. The Company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands. Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients. The Company’s wholly-owned subsidiary, Spire Secure Logistics is a leading provider of customized security programs, compliance, information technology, buildout design, and due diligence services for the legal cannabis, mining and investment sectors. Friday Night Inc. is focused on strengthening and expanding its current operations.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. Friday Night undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE Friday Night Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/March2018/06/c6599.html

Alexia Helgason, Corporate Communications, 604-674-4756 (ext. 1), Alexia@FridayNightInc.comCopyright CNW Group 2018

Source: Canada Newswire (March 6, 2018 – 8:30 AM EST)

The post Friday Night Inc. Closes on Land Purchase Agreement appeared first on CannabisFN.

Hydropothecary Signs Largest Cannabis Supply Agreement in History

Written by Ryan Allway on Mar 05, 2018

Canada’s adult-use recreational marijuana market is just months away from going into effect, and one of the country’s top producers has just inked a tentative deal that will give it a leading edge. The Hydropothecary Corporation (TSX-V: THCX) recently signed a letter of intent to supply its home province of Quebec with 20,000 kilograms of cannabis products in the first year of legalization. That is the largest supply agreement announced in Canada to date, and the company says it is just the beginning.

According to Deloitte, Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years. With recreational cannabis expected to be available by mid-August, provinces have been crafting the rules that will govern the distribution, sale, and consumption of cannabis within their borders. These rules will vary widely between provinces, with some adopting a public retail model and others choosing a public-private retail system.

Quebec has opted for the public model and has tasked the provincial liquor authority, the Société des alcools du Québec (SAQ), with setting up the public corporation responsible for cannabis retail and distribution, the Société Québecoise du Cannabis (SQdC). The SQdC will be the only cannabis retailer in the province, operating from both physical locations and an online store. Starting with 15 stores, the SQdC is expected to rapidly ramp-up to 150+ stores in the first two years.

With Quebec expecting to sell just under 58,000 kg of cannabis in the first year of legalization, Hydropothecary’s letter of intent for 20,000 kg represents 35% of projected market demand in the province. But more than that, the agreement demonstrates the province’s confidence in the company’s ability not only to meet local demand, but to play a crucial role in establishing Quebec as a leader in the newly-developing cannabis business at home and abroad.

“This supply arrangement is an important step for Hydropothecary,” said CEO Sébastien St-Louis in a press release announcing the deal. “We are honoured by the opportunity to supply cannabis in our home province and we want Quebecers to know that we are committed to providing safe and high-quality products for the adult-use recreational market.”

In total, the SAQ has signed supply agreements with six licensed producers (LPs), although Hydropothecary’s order vastly outstrips those of the other companies, including Canopy Growth Corp. (TSX: WEED) at 12,000kg, Aurora Cannabis Inc (CSE: ACB) at 5,000kg and Aphria (TSX: APH) at 8,000kg.

Quebec and beyond

Of the six Licensed Producers signing agreements with the SAQ, Hydropothecary finds itself in an ideal position to take a commanding position in the Quebec market and to plan for even bigger and better things.

For one, it is the only licensed producer of the six headquartered in Quebec, a province which has a proud tradition of favouring locally-produced goods and services. The company has also developed a full range of innovative products including some not found anywhere else. And, recreational consumers will take note, the letter of intent includes the full range of award-winning products currently sold by Hydropothecary, including H2 (flower), Time of Day (flower), Elixir (oil spray), and Decarb (edible powder).

Hydropothecary’s business model is also unique among Canadian LPs vying for top-spot in the newly legal recreational cannabis market. Instead of spreading itself across multiple regions, the company is focusing on establishing leadership and dominance in its home-province of Quebec before moving outward. While digging deep into the Quebec marketplace and developing industry expertise with partners across the province, Hydropothecary is continuing its ambitious expansion plans which currently include finishing a 250,000 square foot greenhouse and construction of another million-foot facility.

By the end of the year, Hydropothecary will be able to grow and process 108,000 kg of cannabis products, making it one of the biggest cannabis companies in the world. With that level of growth, it seems unlikely that the national and international markets are far from Hydropothecary’s sights. In fact, the company has been participating in meetings with the Ontario Cannabis Retail Corporation (OCRC) to supply the neighbouring province’s recreational market.

In the lead up to legalization, supply agreements at the provincial level like this one will have a significant impact on the prospects of licensed producers hoping to secure a piece of the Canadian market. Hydropothecary’s supply agreement with Quebec is the biggest to date and investors may want to take a closer look at the stock before the deal is finalized and the market opens up.

For more information, visit the company’s website at www.thehydropothecary.com.

Disclaimer

The post Hydropothecary Signs Largest Cannabis Supply Agreement in History appeared first on CannabisFN.

Emerald Health Therapeutics and Village Farms International Announce Cannabis Cultivation License for 1.1 Million SF Delta 3 Greenhouse Operation

Written by Ryan Allway on

Unmatched Experience and Expertise and Optimized Facility Design Will Support Continuous Production and Consistent Quality and Supply

VANCOUVER, British Columbia, March 05, 2018 (GLOBE NEWSWIRE) — Emerald Health Therapeutics, Inc. (Emerald) (TSX-V:EHT) (OTCQX:EMHTF) and Village Farms International, Inc. (Village Farms) (TSX:VFF) (OTCQX:VFFIF) today announced that Health Canada has issued a Cultivation Licence for their co-owned Delta 3 greenhouse operation (the “Joint Venture”) under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). This optimally-designed 1.1 million ft² cannabis growing facility is located in one of the best growing climates in Canada in Delta, BC, and is conservatively projected to produce 75,000 kg of quality cannabis annually at full production.

Village Farms and Emerald aim for the Joint Venture to be one of the most consistent and reliable suppliers of quality cannabis products to wholesalers, distributors and retailers across Canada and internationally, with the goal to be the low-cost cannabis Canadian producer at an all-in production cost of less than $1.00 per gram at full production.

The Joint Venture will immediately begin cultivating cannabis in the Delta 3 greenhouse following the transfer of existing starter plants from Emerald and expects to receive its Sales License under ACMPR by July 1, 2018.

“Our Joint Venture is well positioned to be a leading supplier in the imminent legal adult-use Canadian cannabis market, with potentially significant benefit to each of our companies and our shareholders,” said Avtar Dhillon, MD, Executive Chairman of Emerald. “With Emerald’s in-depth cannabis expertise, Village Farms’ know-how based on innumerable crop cycles over 30 years of large-scale greenhouse growing, and working with global agricultural leaders and high-tech facilities and systems experts, we configured this greenhouse for continuous weekly harvesting year-round, maximum operating efficiencies, and flexibility to adapt to an evolving market. We are accomplishing this on a very capital-efficient basis.”

“Growing any agricultural crop on a large scale and repeatedly delivering expected quantities and consistent quality, with full regulatory compliance, at a competitive price is an extremely challenging proposition for even the most experienced agricultural producers. The goal is for the Joint Venture to set the standard in this regard in the Canadian cannabis industry and establish itself as a preferred supplier for both the short- and long-terms,” said Michael DeGiglio, CEO, Village Farms International. “In addition to production ramp-up, in 2018 the Joint Venture will focus on product development and developing its marketing strategy to become a vertically integrated leader in the Canadian cannabis market.”

The Joint Venture is converting the Delta 3 greenhouse operation to cannabis production with meticulous attention to the growing environment and systems, processing areas, and production ramp-up, with a particular focus on management of climate and contaminants, optimizing yield, maximizing efficiencies, and achieving continuous year-round production. Key elements of the design, conversion, and operations include:

Growing system with automation proven in different crops to provide optimal efficiencies;
Industry-leading HVAC systems reflecting hundreds of aggregate years of climate management experience, with technically advanced data systems;
High-tech light deprivation and light supplementation systems with individual control of over 15 growing zones within the 1.1 million ft²footprint;
Fully automated 90,000 square feet nursery capable of supplying Delta 3 (as well as the 1.1 million ft² Delta 2 facility should the Joint Venture exercise its option to purchase that facility, as described below);
State of the art drying, trimming and packaging areas;
Core upgrades to facility infrastructure;
Use of an established labour force and proprietary labour tracking systems; and,
Secure supply of low-cost electricity from BC Hydro sufficient to power Delta 3 at full production (and, if required, to power the Delta 2 facility at full production).

Conversion of the first 250,000 ft² section of the 1.1 million ft² Delta 3 greenhouse to cannabis production is substantially complete and is expected to commence production in April 2018. Senior growing and operational personnel, including the established team transferred from Village Farms, are in place for production ramp up. Conversion of the remainder of the 1.1 million ft² is underway and the entire facility is expected to be in production in 2019.

The Joint Venture holds options on two additional state-of-the-art greenhouses owned by Village Farms (Delta 2 and Delta 1, with 1.1 million ft²and 2.6 million ft² of growing capacity, respectively). Exercising these options would expand the Joint Venture’s production facility to 4.8 million ft²and make it one of the largest cannabis producers in Canada.

About Village Farms International, Inc.

Village Farms is one of the largest producers, marketers, and distributors of premium-quality, greenhouse-grown fruits and vegetables in North America. The food our farmers grow, along with other greenhouse farmers under exclusive arrangements are all grown in environmentally friendly, soil-less, glass greenhouses. The Village Farms® brand of fruits and vegetables is marketed and distributed primarily to local retail grocers and dedicated fresh food distributors throughout the United States and Canada. Since its inception, Village Farms has been guided by sustainability principles that enable us to grow food 365 days a year that not only feeds the growing population but is healthier for people and the planet. Village Farms is Good for the Earth® and good for you.

About Emerald Health Therapeutics

Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) operates through Emerald Health Therapeutics Canada Inc. (“EHTC”), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through EHTC, Emerald is authorized to produce and sell dried cannabis and cannabis oil for medical purposes. It operates an indoor facility in Victoria, BC, and is building a 500,000 ft² greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million ft² to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald owns 50% of a Joint Venture with Village Farms International, Inc. that is converting an existing 1.1 million ft² greenhouse in Delta, BC to grow cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health Group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products that may provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:

Robert Hill
CFO
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Ray Lagace
Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.

We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to statements with respect to build out of the Company’s growing facility and the details thereof; rapid production capacity expansion; estimates of production of cannabis at the Initial greenhouse and the additional facilities discussed herein; the development and potential size of a non-therapeutic adult-use market for cannabis and cannabis extracts; contributions of cash to the JV; the JV becoming one of the world’s premier greenhouse cannabis growers; and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, failure of the federal government to approve legislation legalizing sales of non-therapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; the Company’s historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in the Company’s annual information form and other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.

Source: GlobeNewswire (March 5, 2018 – 8:00 AM EST)

The post Emerald Health Therapeutics and Village Farms International Announce Cannabis Cultivation License for 1.1 Million SF Delta 3 Greenhouse Operation appeared first on CannabisFN.

Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis

Written by Ryan Allway on

Ehave’s Bioinformatics Platform Technology to Be Used to Evaluate Aequus’ Products in Multiple Neurological Disorders

VANCOUVER , March 5, 2018 /CNW/ – Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) (“Aequus” or the “Company“), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (EHVVF) (“Ehave“), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave’s bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017 .

“Our thinking regarding conducting clinical trials of various cannabinoid containing formulations has advanced substantially since we signed the original Letter of Intent with Ehave. We have a number of different trials in late-stage planning and see multiple opportunities for us to leverage our traditional pharmaceutical expertise in designing and implementing clinical programs, but we also see growing opportunities for us to leverage our existing relationships with Canadian clinicians and take advantage of our existing pharmaceutical sales infrastructure to better serve clinicians and Insurers as it relates to medical cannabis. We and Ehave are in a unique position to generate meaningful product safety and efficacy data in a variety of trial settings in a very efficient and cost-effective way,” says Doug Janzen , Chairman and CEO of Aequus. “In our most recent comprehensive physician survey regarding factors that prevent them from recommending medical cannabis products, Canadian clinicians identified the lack of robust clinical data in a real-world setting for such products as a significant limiting factor.”

“Our robust bioinformatics platform allows us to provide customized, next-generation clinical solutions that empower pharmaceutical developers such as Aequus to be successful,” said Prateek Dwivedi , CEO of Ehave. “We are particularly committed to partnering with companies seeking to evaluate medical cannabis products, recognizing the specific need within this emerging industry for ‘pharmaceutical-grade’ patient and clinical data informatics to help unlock the value of these new therapies for clinicians, patients, and payors. Aequus shares this view based on its strong background, unique capabilities and commercial experience in traditional pharmaceutical development, making them an ideal partner for Ehave. We look forward to helping them advance their clinical programs and potentially improve outcomes for patients with neurological disorders who may benefit from Aequus’ products.”

The terms of the agreement are similar to that of the original Letter of Intent. Aequus will pay Ehave a per-patient fee for trials conducted using Ehave’s platform and Aequus will receive patient assessment, diagnostic and therapeutic outcomes and side-effect profile content from formal and informal studies conducted using the Ehave platform, subject to standard patient consent and clinical research ethics approvals. Aequus will own all clinical results and data generated from trials using the Ehave platform.

About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (TSX-V:AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ development stage pipeline includes several products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. With a focus in neurology and other specialty areas, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.

About Ehave, Inc.
Ehave, Inc. (EHVVF) is empowering the mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with leading medical cannabis licensed producers. For more information, visit www.ehave.com.

Aequus Pharmaceuticals Inc. Forward-Looking Statements:
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, and using results from Ehave’s bioinformatics platform to monitor and assess patient outcomes. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company’s ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company’s current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company’s ability to attract and retain skilled staff, market competition, the products and technology offered by the Company’s competitors and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading “Risk Factors” in the Company’s Annual Information Form dated April 29, 2016 , a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com,and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.

Ehave, Inc. Forward-Looking Statement Disclaimer
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,””projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and * the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015 , as amended, which is available on the SEC’s website, http://www.sec.gov.

SOURCE Aequus Pharmaceuticals Inc.

The post Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis appeared first on CannabisFN.

Naturally Splendid Sells Manufacturing Stake to Refocus Efforts

Written by Ryan Allway on Mar 04, 2018

The hemp industry has experienced tremendous growth over the past several years and there are no signs of slowing down. According to the Hemp Business Journal, the CBD market could reach $2.1 billion by 2020 with hemp-based products accounting for $450 million of those sales. This represents a 700 percent increase in revenue from 2016, which makes hemp-based CBDs one of the cannabis industry fastest growing subsets.
Naturally Splendid Enterprises (TSX-V: NSP) (OTCQB: NSPDF) is a biotechnology and consumer products company focused on developing, manufacturing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. After selling its interest in POS BPC Manufacturing Corp., the company has a significant influx of capital that it can use to execute on its strategic business plans.

Naturally Splendid Sells POS BPC Stake

Naturally Splendid acquired a 51 percent interest in POS BPC Manufacturing Corp. on June 15, 2017 for $1,971,000 in cash and stock. After a series of advances in extraction and formulation methods, the company determined that funds that would be required to upgrade BPC to take advantage of these advancements would be better spent expanding capacity at its wholly-owned Pitt Meadows packaging and distribution facility.

On February 22, the company announced the sale of its 51 percent ownership stake for $3,536,650. The transaction represents a gain of $1,565,650 that adds immediate non-dilutive cash to its operations and enables it to explore other opportunities in the space. The company’s goal is to develop its own state of the art facility that will focus on the latest extraction and formulation methods through strategic alliances and partnerships.

“I am very pleased with the decision to sell our position in the BPC facility,” said CEO Doug Mason in the press release announcing the deal. “This immediately adds non-dilutive cash to our operations and allows us to explore and execute on other opportunities the company has been researching. As reported earlier, Naturally Splendid has begun preparing a submission to become a Licensed Dealer of cannabis extracts under the Canadian regulatory regime.”

In the meantime, the company announced that it has identified third-party manufacturers facilities to produce its proprietary, HempOmega™, Hemp Emulsion and Hemp Protein Isolate (provisional patent) products. The company’s intellectual property has already attracted interest from notable food manufactures both domestically as well as internationally, with HempOmega(™) already being commercialized in multiple products. These products help to insulate the company somewhat from while cannabis regulations continue to evolve in Canada.

Focused on Building Its Own Operations

Naturally Splendid is a leader in hemp-derived products with many retail products under the NATERA®, Elevate Me™,CHII™ and Pawsitive FX™ banners and intends to expand that reputation into the emerging cannabidiol (CBD) space with a growing line up of products and services.

In late 2017, the company acquired Prosnack Natural Foods Inc., who are the makers of the Elevate Me™ brand. Prosnack produces energy bars, protein bars, snack bites, balls, oatmeals, etc. Additionally, they develop custom formulations for nationally recognized brands and co-pack/private label for many large retailers in Canada and the U.S. The goal of this acquisition was to have ready products to be fortified with CBD in anticipation of legalization in 2018 in Canada.

The company’s primary focus is currently on its consumer and pet product lines, including its CHII™, NATERA™, Elevate Me™, and PawsitiveFX™ products, with several new exciting line extensions under development. With hemp’s many benefits, these products cover a diverse range of consumer categories, including functional foods, cosmetics, and pet supplements. The products are sold through both ecommerce and traditional retail distribution channels in the United States and around the world.

The company’s Pitt Meadows production, processing, packaging, and distribution facility fulfills internal packaging needs for its house branded products, as well as capacity for co-packaging opportunities with other businesses. The facility will include extraction and manufacturing multiple CBD fortified products upon receiving their Dealer License. In addition, the facility provides private labeling for major retailers throughout the country, as well as co-packing for global manufacturers, with gross revenue of about C$17.5 million over the past four years.

In recent months, the company has outlined its strategy to become a Licensed Dealer in Canada, where the legalization of CBD nationwide could open the door to a significant market opportunity. Becoming a Licensed Dealer will allow the company to manufacture, distribute, and export hemp and marijuana extracts. The Hemp Business Journal projects that the global market for CBD will reach $2.1 billion by 2020, with $450 million of those sales coming from hemp-based sources. That’s a 700 percent increase in the market, making hemp one of the fastest growing industry subsets.

Looking Ahead

Naturally Splendid Enterprises (TSX-V: NSP) (OTCQB: NSPDF) represents a compelling investment opportunity in the hemp-based CBD space. With the sale of its POS BPC Manufacturing Corp. interest, the company has fresh capital that it can use to deploy into other areas of its business or pursue new strategic acquisitions. Investors may want to keep a close eye on the stock over the coming quarters as it executes on these plans.

Disclaimer

The post Naturally Splendid Sells Manufacturing Stake to Refocus Efforts appeared first on CannabisFN.

RavenQuest Expands National Presence; Completes Bloomera Acquisition

Written by Ryan Allway on Mar 02, 2018

VANCOUVER, British Columbia, March 02, 2018 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (CSE:RQB) (the “RavenQuest”) is pleased to announce that it has completed the acquisition of 8649081 Canada Inc. (“Bloomera”), a Markham, Ontario based licensed producer of cannabis under the Access to Cannabis for Medical Purposes Regulations.

Under the terms of the transaction, the Company has acquired all of the outstanding share capital of Bloomera in consideration for a cash payment of $15,000,000, and the issuance of 10,400,000 common shares to the existing shareholders of Bloomera.

Bloomera currently holds a Health Canada License to Cultivate and will initially add approximately 2,000 kilograms of annual production of cannabis to RavenQuest’s investment division. RavenQuest also owns Alberta Green Biotech, an Edmonton facility with expected annual production of approximately 7000 kilograms which will be ready for cultivation in mid-summer 2018. Given RavenQuest’s growing methodology and application of yield-maximization research being developed in partnership with McGill University, RavenQuest expects to produce at least 11,000 kilograms of cannabis annually from these two facilities.

“Closing this transaction marks a significant milestone for our company. With the addition of Bloomera, we are delighted to now have direct access to the Greater Toronto Area (GTA), Canada’s largest cannabis market. From a diversification perspective, this addition perfectly complements our western Canadian exposure in Alberta. When you look at our presence in Ontario and Alberta, two of the nation’s most dynamic cannabis markets, we feel this is a powerful combination of market exposure as we continue to build a national and ultimately global cannabis company. We will add to our portfolio on a selective basis where we see strategic benefit” stated George Robinson, CEO of RavenQuest. “The Bloomera acquisition accelerates our growth trajectory by at least six months as we begin to incorporate our revolutionary grow methodologies into production. This means we have presence with funded capacity in key provincial markets, nicely timed to coincide with the Cannabis Act becoming law of the land in Canada.” he continued. “Strategically Bloomera is a tremendous fit with RavenQuest.”

About RavenQuest BioMed Inc.

Ravenquest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications (604) 484-1230

Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including statements with respect to the development of a licensed cannabis production facility and anticipated production from such a facility. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

The post RavenQuest Expands National Presence; Completes Bloomera Acquisition appeared first on CannabisFN.

SinglePoint Looks to Apply Blockchain to Healthcare with New LOI

Written by Ryan Allway on

The healthcare system is fraught with dangers and inefficiencies, from electronic health records to counterfeit pharmaceuticals. Blockchain technologies have the potential to revolutionize the industry with an immutable ledger of information for patients, physicians, and payors. These records could create solutions like manufacturing-to-consumer supply chain verification or standardized medical health records to lower costs and address other issues.

SinglePoint Inc. (OTCQB: SING) recently announced its entry into the blockchain healthcare space with its letter of intent with ORHub, a technology provider that aims to make operating rooms much more efficient.

Blockchain in Healthcare

Blockchain technology is best-known for powering Bitcoin, but its applications move well beyond the financial sector. Wal-Mart and IBM are collaborating to build a blockchain platform for tracking food procurement in China, BHP is testing a program to track mineral samples using Ethereum, and the start-up Everledger has already been tracking more than one million diamonds from mine-to-consumer since May of 2015.

Electronic health records, or EHRs, are a prime example of where blockchain technology could dramatically improve efficiency. Physicians and surgeons often treat acutely ill patients without access to medical histories, current medications, and prior imaging studies that could influence their patient care because EHRs lack interoperability and entail high costs. Blockchain technology could lower these costs and make these records highly standardized.

Fraudulent Medicare billing is another area where blockchain technology could help solve a key problem costing more than $60 billion per year. An immutable blockchain that informs patients of all changes to their healthcare records and bills would eliminate any possibility of abuse, while increasing the safety of drug and device supply chains. In fact, blockchain technology that track every step of the pharmaceutical procurement and delivery process are in development.

SinglePoint’s New Letter of Intent

SinglePoint recently announced a letter of intent with ORHub Inc. (OTC Pink: ORHB) to build out a blockchain services platform for healthcare applications. Under the proposed agreement, the company will design and develop a blockchain-based solution for ORHub to enhance the value of data collected by its operating room software platform. ORHub will contribute $750,00 to cover initial development costs of the blockchain-based platform.

“The healthcare blockchain initiative with SinglePoint is an exciting development for us at ORHub,” said OrHub CEO Colt Melby in the press release announcing the LOI. “Our vision is to dramatically lower surgical costs, create time efficiencies while improving patient outcomes by capturing relevant surgical data and deploying this information through blockchain solutions to provide instant access or doctors, patients, and hospital administrators.”

SinglePoint believes that the LOI with ORHub represents just the beginning of many similar agreements to build out blockchain technologies across different industry verticals. With the commitment to fund the project, the company is in a strong position to design, develop, and execute on the solution in collaboration with key blockchain engineers. These develops help solidify its leadership position in one of the world’s fastest growing markets.

Looking Ahead

SinglePoint Inc. (OTCQB: SING) represents a unique opportunity to profit from the proliferation of blockchain technology and its potential in the healthcare industry. With its recent letter of intent, the company gains capital to begin its buildout as well as a key proof of concept when it comes to demonstrating its ability to execute. These factors could lead to more business down the road as it moves into horizontal markets.

Investors may want to take note of these developments, particularly after it completed its uplisting to the OTCQB and added Venugopal Aravamudan as a board member.

For more information, visit the company’s website at www.singlepoint.com.

Disclaimer

The post SinglePoint Looks to Apply Blockchain to Healthcare with New LOI appeared first on CannabisFN.

Abattis Announces Successful Completion of Acquisition of Gabriola Green Farms

Written by Ryan Allway on

VANCOUVER, British Columbia, March 02, 2018 (GLOBE NEWSWIRE) — Abattis Bioceuticals Corp.(the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce that, further to its news release dated February 27, 2018, it has completed its acquisition (the “Acquisition”) of a 90% ownership interest in Gabriola Green Farms Inc. (“Gabriola”).

Gabriola is a British Columbia company that has applied for a license to produce (an “LP”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing.

“We are excited to complete our acquisition of Gabriola. Gabriola’s anticipated LP will complete our suite of downstream offerings and be the highlight of our growth into a full-service cannabis company,” stated Rob Abenante, Abattis President and CEO.

Gabriola currently has plans for an approximately 26,000 square-foot production facility to produce medical-grade marijuana located on 18 acres in the agricultural land reserve on Gabriola Island, BC. The facility will include a level 8 security vault.

Gabriola’s production facilities are expected to be constructed in two phases:

Phase 1 – Buildout of its 6,000-square-foot state-of-the-art facility, consistent with ACMPR standards.
Phase 2 – Upon completion of the Phase 1 buildout, Gabriola will build out an expansion of approximately 20,000 square feet.

In connection with the Acquisition, the Company issued an aggregate of 61,307,902 common shares of the Company and paid $2.5 million in cash to the shareholders of Gabriola. In connection with the Acquisition, Abattis has also secured (i) a right of first refusal on the remaining 10% ownership interest in Gabriola from CannaNUMUS Blockchain Inc. and (ii) an option to acquire the lands on which Gabriola’s operations are conducted for $7 million until February 27, 2023 from an unrelated third-party.

About Abattis Bioceuticals Corp.

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante”

Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: GlobeNewswire (March 2, 2018 – 8:42 AM EST)

News by QuoteMedia

The post Abattis Announces Successful Completion of Acquisition of Gabriola Green Farms appeared first on CannabisFN.

Choom™ Common Shares Now DTC Eligible

Written by Ryan Allway on

VANCOUVER, March 2, 2018 /CNW/ – Choom™ (CSE: CHOO; OTCQB: CHOOF) is pleased to announce it has received processing approval from The Depository Trust Company (“DTC”) of New York, NY and is now DTC eligible. Being DTC eligible is expected to greatly simplify the process of trading and exchange of the Company’s common stock on the OTC marketplace in the United States.

Choom Holdings Inc. (CNW Group/Choom Holdings Inc.)

The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC, that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.

The Company’s common shares are quoted for trading on the OTCQB, a U.S. interdealer quotation system, under the symbol “CHOOF“. Chooms’ common shares principally trade and are listed on the Canadian Securities Exchange under the symbol “CHOO”.

SAY HELLO TO CHOOM™
Choom™ was created for and inspired by the Choom Gang; a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom”. Now, after four decades, Choom™ is bringing the spirit of Hawaii to the Okanagan and Canada. We’re planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb. Added Choom™ will provide an amazing experience for customers, and bring style, sophistication and fun to the cannabis market through our Choom™ stores.

“Chris Bogart”
President & CEO

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Choom Holdings Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/March2018/02/c8349.html

Choom Holdings Inc., Chris Bogart, President & CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.caCopyright CNW Group 2018

Source: Canada Newswire (March 2, 2018 – 8:00 AM EST)

News by QuoteMedia

The post Choom™ Common Shares Now DTC Eligible appeared first on CannabisFN.

Friday Night Inc. Closes Acquisition of Spire Secure Logistics and Strengthens Team

Written by Ryan Allway on

Vancouver, British Columbia (FSCwire) – Friday Night Inc. (the Company or Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF) is pleased to advise that it has closed its previously announced acquisition of Spire Secure Logistics Inc. (“Spire”). 7,692,308 common shares were issued at a deemed price of $0.65 to the shareholders of Spire. These shares are subject to trading restrictions until July 2, 2018 and are further subject to a voluntary escrow that will see 12.5% of the total amount released every 3 months, starting with a release on closing and then on May 1, 2018. Brayden Sutton, CEO of Friday Night, held less than 10% of Spire, and took no part in the negotiations with Spire and the decision by the board to acquire Spire.

Spire Strengthens Team

The Company is also pleased to announce that Tim Humberstone, a former law enforcement leader and respected expert in Canada’s regulated cannabis sector is joining Spire Secure Logistics, a company specializing in security, intelligence, and compliance. As Chief Strategy Officer, Tim will lead Spire’s growth in Ontario and support clients across Canada with his depth and breadth of specialized knowledge and relationships.

“Anyone who knows Tim Humberstone knows that he is a consummate professional – and there is nobody who knows cannabis security and compliance better,” said Spire’s CEO Andy Richards.

“I’ve been courted by a lot of companies in the cannabis sector,” said Mr. Humberstone. “It’s no accident I chose to join the team at Spire Secure Logistics. Spire has been quietly establishing a presence across Canada, and I’m excited to take the lead in Ontario.”

Mr. Humberstone led security and compliance at one of Canada’s first Licensed Producers of medicinal cannabis. He worked closely with Health Canada and the Office of Medical Cannabis since the earliest days of the regulated cannabis sector. He served in the regulated roles of Senior/Responsible Person in Charge, created all security related policies and procedures, and was responsible for extensive applications and reporting.

During a prior 20-year career with the RCMP, Humberstone gained leadership experience including municipal and federal drug enforcement, the Organized Crime Agency, and Combined Forces Special Enforcement Units. He trained extensively in advanced policing and leadership roles, including expertise in federal and provincial policies. He has strong relationships with federal, provincial, and municipal law enforcement agencies.

About Spire Secure Logistics:

Spire is a security and intelligence company with expertise in law enforcement training, high-risk mining security, and the cannabis sector. With services including compliance, information technology, buildout design, security program implementation, and due diligence, Spire aims to be the global leader in designing security programs and solutions for the legal cannabis sector.

About Friday Night Inc.

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada. The company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands. Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients. Friday Night Inc. is focused on strengthening and expanding these operations within and outside of the state.

For further information please contact:

Alexia Helgason, Corporate Communications
604-674-4756 (ext. 1)
Alexia@FridayNightInc.com

To view the associated document to this release, please click on the following link:
public://news_release_pdf/fridaynight03022018.pdf

To view the original release, please click here

Source: Friday Night Inc (CSE:TGIF, OTCQB:TGIFF, FWB:1QF)

To follow Friday Night Inc on your favorite social media platform or financial websites, please click on the icons below.

The post Friday Night Inc. Closes Acquisition of Spire Secure Logistics and Strengthens Team appeared first on CannabisFN.

RavenQuest Completes Financings for $24.5 Million

Written by Ryan Allway on

VANCOUVER, British Columbia, March 02, 2018 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) has completed the first tranche of its previously-announced brokered private placement (the “Brokered Placement”) of units (each, a “Unit“) and convertible debenture units (each, a “Debenture Unit“) of the Company, with Haywood Securities Inc. (“Haywood”) acting as lead agent. In connection with completion of the Brokered Placement, the Company issued 3,581,300 Units at a price of $1.25 per Unit, and 15,000 Debenture Units at a price of $1,000 per Debenture Unit, for aggregate gross proceeds to the Company of $19,476,625. The Company also completed a concurrent non-brokered private placement (the “Non-Brokered Placement” and, together with the Brokered Placement, the “Offering”) of 4,052,000 Units, for additional gross proceeds to the Company of $5,065,000. The aggregate gross proceeds to the Company from the Offering was $24,541,625.

“The closing of this financing represents an integral step toward closing the acquisition of RavenQuest’s first licensed facility” stated George Robinson, Chief Executive Officer of the Company. “We are thrilled to see that both segments of the offering were oversubscribed, demonstrating the high-level of confidence that the market has in our company’s unique combination of innovation, strategic vision and execution. RavenQuest is appreciative of this confidence and fully intends to surpass expectations as we continue our growth strategy throughout 2018 and beyond.” Robinson continued by stating “in addition, the oversubscription of this financing funds the construction of Alberta Green Biotech, our Edmonton facility which is scheduled for completion in mid-2018. At this point, all of our 11,000-kilogram production capacity is fully funded.”

Each “Unit” consists of one common share of the Company, and one common share purchase warrant (each, a “Warrant“). Each Warrant is exercisable to acquire an additional common share of the Company at a price of $1.50 per a period of twenty-four months, subject to acceleration in the event that the closing price of the Company’s common shares on the Canadian Securities Exchange is greater than $2.75 for a period of ten consecutive trading days.

Each “Debenture Unit” consists of an unsecured convertible debenture of the Company in the principal amount of $1,000 (each, a “Debenture“) and 690 Warrants. The Debentures are convertible at the option of the holder into common shares at a price of $1.45 per share, bear an interest rate of ten percent per annum and mature twenty-four months after the date of issue.

The proceeds of the private placement will be used by the Company to finance the acquisition of 8649081 Canada Inc. (“Bloomera“), and for general working capital purposes. Bloomera is a licensed producer of cannabis under the Access to Cannabis for Medical Purposes Regulations based in Markham, Ontario. The acquisition of Bloomera is expected to close shortly.

In connection with the Brokered Placement, the Company paid a commission of $1,558,130, of which $932,952.50 was issued in Units at a deemed price per Unit of $1.25 and $625,117.50 was paid in cash, and issued to the Agent 1,178,090 compensation options (each, a “Compensation Option“). Each Compensation Option entitles the holder to acquire a common share of the Company at a price per common share of $1.25 for a period of twenty-four months from the closing of the Offering. As additional compensation, the Company paid to the Agent a corporate finance fee equal to $80,000 in the form of Units at a deemed issue price of $1.25 per Unit and issued to the Agent 64,000 corporate finance compensation options, having the same terms and attributes as the Compensation Options.

All securities issued in connection with the Offering are subject to a statutory four-month-and-one-day hold period, in accordance with applicable securities legislation.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About RavenQuest BioMed Inc.

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications 1-877-282-1586

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including statements with respect to the completion of a further tranche of the brokered private placement and the acquisition of a licensed cannabis producer. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

The post RavenQuest Completes Financings for $24.5 Million appeared first on CannabisFN.

Naturally Splendid Appoints New CFO

Written by Ryan Allway on Mar 01, 2018

VANCOUVER, British Columbia, February 28, 2018 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSX-V:NSP) (OTCQB:NSPDF) (Frankfurt:50N) is pleased to announce that it has appointed Sead Hamzagic as Chief Financial Officer effective immediately , replacing Brian Richardson, who will continue to be a resource for the Company in an advisory board capacity.

Mr. Hamzagic has over 30 years of public practice accounting and financial management experience with a variety of public and private companies. As a designated CPA-CGA, Mr. Hamzagic has developed a unique suite of expertise in overseeing corporate finance activities, financial planning & analysis, public reporting, as well as mergers and acquisitions, including 10 years with sparkling water producer Clearly Canadian Beverage Corporation, and most recently as the CFO of a number of TSX Venture listed companies.

Naturally Splendid CEO Mr. Douglas Mason states, “Mr. Hamzagic will play an important role as CFO in ensuring NSE’s continued growth. He will plan and implement the management and control of all financial activities related to the business accounting, finance, forecasting, strategic planning, mergers and acquisitions, asset management and analysis and negotiations.”

“Naturally Splendid has tremendouse potential. I am looking forward to working alongside their talented management team, where I can provide financial leadership to assist in building on NSE’s goal of delivering value to its shareholders,” said Mr. Hamzagic

Naturally Splendid would like to thank Mr. Richardson who has served as CFO for Naturally Splendid since 2016. Mr. Richardson will assist Mr. Hamzagic with the transition.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and non-psychoactive cannabinoid compounds in a broad spectrum of applications.

Naturally Splendid currently has four innovative divisions:

(1) BIOTECHNOLOGY – Focused on three major platforms:

(1) Proprietary HempOmega™ encapsulation

(2) Extraction and formulation with Cannabidiol (CBD)

(3) Hemp and plant-based proteins.

(2) CONSUMER PRODUCTS

· NATERA® – brand of retail hemp and superfood products distributed throughout North America, Asia and Europe.

· Prosnack Natural Foods Inc. (Elevate Me™) – lifestyle brand of healthy meal replacement products distributed throughout North America.

· Chi Hemp Industries Incorporated (CHII) – e-commerce platform for natural and organic hemp products.

· PawsitiveFX® – topical pet care products.

· NATERA®CBD – retail hemp-based cannabinoid nutraceutical and cosmeceutical products distributed in Asia.

· NATERA®Skincare – brand of retail hemp based cosmeceutical products.

(3) NATERA® Ingredients – bulk ingredients including HempOmega™.

(4) Co-Packaging/Toll-Processing – packaging for house-brands (NATERA®, CHII and Elevate Me(TM)) and third-party partners.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors

Mr. Douglas Mason

CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.

(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)

#108-19100 Airport Way

Pitt Meadows, BC, V3Y 0E2

Office: (604) 465-0548

Fax: (604) 465-1128

E-mail: info@naturallysplendid.com

Website: www.naturallysplendid.com

The post Naturally Splendid Appoints New CFO appeared first on CannabisFN.

WeedMD to Secure Dealer’s License from Health Canada as a Next Step in its R&D Strategy

Written by Ryan Allway on

WeedMD Inc. (WMD.V) (WDDMF) (4WE.F) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, has submitted an application to obtain a Health Canada Dealer’s License (“Dealer’s License”) under the Controlled Drugs and Substances Act (“CDSA”) and its associated regulations. The Dealer’s License will enable WeedMD to conduct research and development (“R&D”) and store cannabis derivatives that are not currently covered under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Dealer’s License also positions the Company to export cannabis oils and concentrates to international markets, as well as to process natural health products.

“As we ramp up our cannabis production to a rate of more than 20,000 kg annually, the Company will be supporting its commercial initiatives with R&D to expand its product offerings for domestic and international markets. With our new state-of-the-art laboratory at the Aylmer facility, we will be able to conduct research to bring novel formulations and dosing methods to market with a Dealer’s License,” said Dr. Luc Duchesne, Chief Scientific Officer of WeedMD. “Additionally, we will be able to test cannabis products in-house which will increase efficiencies and enable us to collect valuable data about strains and their desired effects.”

This is another R&D initiative that WeedMD is undertaking, having recently announced its partnership with the world-renowned Technion-Israel Institute of Technology here. Under the WeedMD-Technion partnership, WeedMD will submit 25 of its strains for inclusion in the Cannabis Data Project, which maps strains and their efficacy in treating certain medical conditions. As there are only a limited number of Dealer’s Licenses amongst the 90 Licensed Producers in Canada, securing this license is a critical step in advancing WeedMD’s medical and recreational growth strategies. The Company will work both independently and with research institutions to accelerate innovation for cannabinoid applications and delivery systems and further its position in the global cannabis market.

About WeedMD Inc.

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands.

The Company is focused on providing medical cannabis to the long-term care, assisted living and seniors’ markets in Canada through its specialized and comprehensive platform.

It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

For more information, access our investor presentation here.

The post WeedMD to Secure Dealer’s License from Health Canada as a Next Step in its R&D Strategy appeared first on CannabisFN.

Friday Night Diversifies Business, Revenue with Acquisition

Written by Ryan Allway on

Canada’s existing medical marijuana program is among the most advanced and complete in the world. The licensing procedures are tightly controlled, and distribution is done via mail to patients with doctor approval. With recreational legalization approaching this summer, that framework is going to be retooled into a much more diverse and free-ranging retail operation that will be governed by varying provincial regulations. In short, compliance and security for Canadian cannabis companies is about to get a whole lot more complex. Add that to the already complex and confusing regulatory landscape in the United States, along with legalization efforts (both recreational and medical) across the globe, and it’s clear there is a market opportunity here.

Friday Night Inc. (CSE: TGIF) (OTCQB: TGIFF), recognizing the importance of security and compliance in the unfolding industry, recently announced the acquisition of Spire Secure Logistics Inc. The move accomplishes a number of things for Friday Night, including the diversification of its revenue stream, entry into international markets, the addition of experienced talent to its team, and further assurance of its own security and compliance efforts.

How Spire Secure Logistics Fits

Spire was founded by CEO Andy Richards (34 years of law enforcement experience with a particular focus on organized crime investigations and a deep familiarity with complex, often international cases) and COO Jeff Meyers (24 years of law enforcement, including organized crime and cross-border regulation, coupled with recent international security for mining interests). Richards and Meyers were acutely aware of the role the black market plays in cannabis and founded Spire to help companies avoid issues as the industry gains traction.

Spire has recognized a need for mitigating regulatory and compliance risks through investigative due diligence – both proactively and in particular during transactions. Recent issues both inside and outside the cannabis space have demonstrated that circumstances involving undisclosed personnel issues, compliance concerns, or other sources of risk have had a negative effect on shareholder confidence. Spire secures shareholder value in a world of known and unknown threats, focusing on maximizing upside potential, while protecting against downside risk.

In a recent conversation, Mr. Richards stated, “We anticipate signing our 7th and 8th clients this week, with 20 more prospective clients in discussions and a deep business development pipeline behind that.” Friday Night has committed an investment of $1 million to expand Spire’s client base, both in Canada and globally.

The acquisition not only expands Friday Night’s revenue stream and international presence, it also gives the company an expert’s view on its own security and compliance issues. With the addition of Mr. Richards to the Friday Night Board of Directors, the company has expert guidance as well in terms of the evaluation of security risks in any potential acquisition or partnership.

As Friday Night CEO Brayden Sutton stated, “Spire is uniquely equipped to keep companies safe, secure, and compliant – which in turn creates more shareholder value and peace of mind. I am extremely honored to call the Spire team a part of our family and look forward to the increased level of intelligence and awareness it brings us as a company, whether that be in current operations or when evaluating other opportunities in the sector.”

Friday Night Developments

As Friday Night Inc. diversifies into other market sectors, it continues to build shareholder value in its foundational cultivation business. The company’s 91% owned Alternative Medicine Association (AMA), the first cannabis cultivator licensed in Las Vegas. AMA also manages the cultivation operations next door, for Harvest Foundation, another cultivation licensee. Friday Night has an agreement to acquire Harvest Foundation in full. When completed, the acquisition would basically double the company’s cultivation capacity, helping it grab a larger share of the fairly recent Nevada recreational market.

The company’s other main subsidiary, the 91% owned Infused MFG, produces hemp-based CBD products. Infused recently introduced its products into California with great success, leading to the addition of two more sales reps to further expand distribution. Friday Night sees the early success in California as an extremely encouraging sign and expects the company’s Canna Hemp brand to continue strong sales growth in both existing and new markets.

Friday Night also recently announced eligibility with The Depository Trust Company (DTC), meaning its stock is now more easily and efficiently traded electronically than in the past. DTC eligibility opens the stock to investors who previously may have avoided it due to trading difficulties, and could lead to a more liquid market for the shares.

Looking Ahead

Friday Night Inc.’s acquisition of Spire Secure Logistics Inc. is a sign of a company in smart growth mode, in a quickly expanding and constantly changing industry. As the cannabis sector gains legitimacy, security and compliance are more important than they ever have been. The addition of Spire shows that Friday Night recognizes the opportunity both to expand its presence in the emerging security sector, as well as to ensure its own compliance as the company expands operations.

Disclaimer

The post Friday Night Diversifies Business, Revenue with Acquisition appeared first on CannabisFN.

Choom Crystallizes Commitment to Recreational Branding with New Hire

Written by Ryan Allway on

As the cannabis industry matures and grows, the differentiation of products and brands in the marketplace becomes critical. With the pending legalization of adult-use recreational marijuana in Canada, the marketing of positive and relatable brands will likely define who is successful and who falls by the wayside as the focus moves from medicinal to recreational products.

Choom Holdings Inc, (CSE: CHOO) (OTCQB: CHOOF) is a Canadian company that is committed wholeheartedly to the recreational marijuana market. While many established companies are having to switch gears (and make major acquisitions and investments) to adapt from the medical to the adult-use market, Choom™ was founded purely as a recreational brand. The company’s recent appointment of a new SVP of Marketing further demonstrates that commitment.

Importance of Retail Lifestyle Marketing

Choom announced the appointment of Chris Gagan as Senior Vice President of Marketing. Mr. Gagan brings an impressive background in retail marketing to the team, and will help to guide the company’s strategy in creating and growing a leading recreational brand.

Mr. Gagan was most recently with Canadian Tire (TSE: CTC.A), a nationwide retailer of automotive supplies, sporting goods, and housewares. He led the creation and execution of several in-house apparel brands, leading efforts from product design to marketing to sales execution. His products garnered $60 million in yearly sales. Prior to that, he was instrumental in the development and sales of a wide range of consumer products for Sugoi Performance Apparel, a division of Dorel Sports (TSE: DII.B) and Fox Racing Inc, a privately held globally recognized action sports brand.

Mr. Gagan’s experience in creating, implementing and selling brands that promote and represent a lifestyle should prove invaluable to Choom. Lifestyle brands are positioned to embody the interests and attitudes of a culture or a group, with the product contributing to the consumer’s chosen lifestyle. That type of identification will likely be very important to marijuana consumers, and Choom is positioned with both its concept and its team to effectively broadcast a healthy and relaxed lifestyle to those consumers.

The Choom™ Concept

The Choom™ brand was inspired by the Choom Gang, Hawaiian locals in the 1970’s who were committed to the relaxed spirit of good times and who loved to smoke choom, the slang term for marijuana. President Obama has even referred to his experiences as part of the Choom Gang. Choom Holdings is focused on bringing those positive and relaxed vibes to the Canadian recreational consumer through a combination of high-grade handcrafted cannabis and stylish, professional retail stores that are inviting to the curious cannabis consumer who might not feel so comfortable going into a more traditional head shop.

Recent deals in the cannabis industry have highlighted the need to shift marketing concepts from medical to recreational, and the deals are not small. Alcohol conglomerate Constellation Brands invested about $245 million in Canopy Growth with the idea to develop and market cannabis-based beverages. Aphria bought Broken Coast Cannabis for $230 million for its recreational potential, and also committed $12.5 million to the newly-formed Hiku Brands which is focused on recreational branding and distribution.

Choom Holdings owns one late-stage Licensed Producer applicant in the interior of British Columbia, and is nearing the acquisition of another late-stage applicant on Vancouver Island. Completion of the licensing process will be a great move forward for the company. But just as important will be the execution of the lifestyle branding strategy. Plenty of companies are producing marijuana, but as the recent industry deals demonstrate, many of them don’t have the capacity or experience to market their products to a broader audience in search of a good time. It appears that the pieces are in place for Choom™ to do just that.

Disclaimer

The post Choom Crystallizes Commitment to Recreational Branding with New Hire appeared first on CannabisFN.

Helix TCS Expands Operations into California Market

Written by Ryan Allway on

The cannabis industry is projected to exceed $50 billion in annual revenue over the coming years, according to Cowen & Co., driven by the legalization of adult-use cannabis across many states. In particular, the legalization of adult-use cannabis in California has created the single largest market in the world for the drug. Investors have many options to capitalize on the market, but some companies are taking more innovative approaches than others.

Helix TCS Inc. (OTCQB: HLIX) recently announced an expansion into California’s cannabis market, which represents a unique opportunity for the company and its shareholders. While the company initially provides security, transportation, and compliance services, management aims to leverage its growing suite of software solutions to provide a wider scope of value added services.

Expanding into California

Helix TCS recently announced that it has begun moving into the California market to support both current and new clients. These services include its security, transportation, and compliance services targeting cultivators, dispensaries, and other companies in the legal cannabis sector. The move represents its first major foray out of Colorado, where it initially began operations after the state legalized adult-use cannabis several years ago. Helix TCS has stated that it plans to move into several new markets in the coming months.

“Helix TCS continues to execute tightly on its strategic plan, and we intend to grow in the California market with the same speed and success that we’ve had in the Colorado market,” said CEO Zachary L. Venegas in a press release announcing the company’s entry into the California market. “We continue to hone our service offerings and service delivery to help our customers operate as safely, efficiently, and profitably as possible.”

Many analysts believe that California’s market could be worth upwards of $5 billion in annual revenue. With the state implementing its new regulations, under the Control, Regulate and Tax Adult Use of Marijuana Act, it’s an ideal time for ancillary service providers like Helix TCS to step in and build up their presence. Many cultivators and dispensaries require both compliance consulting and transportation and security services to meet regulatory demands.

A Data Driven Approach

Helix TCS is a premier provider of integrated operating environment solutions for the legal cannabis industry, including transportation, armed and unarmed guarding, training, investigation, and special services. By providing these ancillary services, the company generates a consistent stream of revenue while building up a large client base who require multiple services.

The company’s flagship software platform is Cannabase, the oldest and largest wholesale platform in the cannabis industry. Management anticipates that Cannabase will become a critical component of its technology initiatives, enhancing its data, security, and compliance offerings with its industry-leading online platform for cannabis businesses, advertisers, and consumers as its full feature set is revealed to the market. The data generated by the platform could also become a key competitive barrier to entry.

In addition to Cannabase, the company has been consolidating its ownership stake in BioTrackTHC, an industry leading seed-to-sale platform. After acquiring, all of BioTrackTHC’s preferred stock, the company controls a nearly 20 percent stake in the firm in conjunction with its partner Rose Capital. BioTrackTHC’s solutions are already used in state governments, including Delaware, New Mexico, Illinois, New York, and Hawaii, as well as a large share of commercial license holders.

Looking Ahead

Helix TCS Inc. (OTCQB: HLIX) represents a compelling investment opportunity in the burgeoning cannabis sector. Rather than cultivating or selling cannabis, the company has focused on providing ancillary services, like security, transportation and compliance. Management has leveraged the clients from these services to build up its technology platform, setting the stage for its next strategic phase.

For more information, visit the company’s website at www.helixtcs.com.

Disclaimer

The post Helix TCS Expands Operations into California Market appeared first on CannabisFN.

International Cannabrands Ltd. Announces Launch of Retail Strategy to distribute JuJu Royal™ Products

Written by Ryan Allway on

Calgary, Alberta (FSCwire) – International Cannabrands Inc. (CSE:JUJU.A; FSE:31G; US OTC:GEATF) (the “Company”) is pleased to announce that it has entered into an agreement with Cathedral City Care Collective, a dispensary in Cathedral City, California, to launch the first dedicated section of a store to JuJu Royal Products. The “store within a store” concept is one of the retail strategies the Company intends to utilize.

Cathedral City Care will dedicate a section of its store to the full range JuJu Royal Products, including merchandise. “Cathedral City Care was particularly drawn to Julian Marley and the Rastafarian culture that the JuJu Royal brand embodies. We are very pleased to have this knowledgeable, compassionate group of people to be the first to feature the JuJu Royal Products in their store and we welcome them to the JuJu family,” said Jeffrey Britz, Chairman and CEO.

Marijuana has a legitimate place in the Rastafarian religion. Marijuana is a companion plant to humans, given by higher powers as an aid and medicine. In the mind of a Rastafarian, the plant is a medicine that helps them to let living in a sustainable way be sufficient. It’s a means to achieve a sense of sufficiency, Earth’s way of helping people to live in harmony with her. For more information on the role of marijuana in the Rastafarian culture see the Blog section on jujuroyal.net.

Cathedral City Care takes pride in the patient friendly atmosphere of its store, belief in their products and its relationship with its patients and customers. Their store features a lounge, pool table, music and great people with an emphasis on the “vibe”. They carry numerous products ranging from flower, extracts, edibles, topicals, accessories and pre-roll. The JuJu Royal display is expected to be ready in the next 3 or 4 weeks with the assistance of Cameron Rose, Sales Representative and Brand Ambassador for International Cannabrands.

About Cathedral City Care Collective

Cathedral City Care Collective was established in 2016, to serve the Coachella Valley. It has been proudly serving medical patients, until the recent legalization of marijuana in California, when it also welcomed recreational adult users to its community. It is located at 28201 Date Palm Drive Suite B, Cathedral City CA 92234. Nick and Lisa Hughes (Owners) with Richard McIntosh – General Manager and Meagan Hogg – Manager, take great pride in providing “good music, good people, good vibes” to their customers.

About International Cannabrands

International Cannabrands acquired the exclusive rights to Julian Marley’s JuJu Royal™ brand to educate people about the natural connection between Julian Marley, Rastafarian culture, reggae music, and marijuana. International Cannabrands generates revenue from licensing brands to growers, edible manufacturers, oil extractors, producers of ancillary products and apparel in the United States where cannabis has been legalized at the state level, as well as products containing CBD in the US and internationally. Select JuJu Royal products are available in California, Washington, Colorado and Puerto Rico with CBD-only products available in the U.K., the birthplace of Julian Marley. The Company is looking to expand JuJu Royal into Nevada in the near future. The company was founded in 2014 and is based out of Denver, Colorado. The Company believes as the market becomes saturated with products varying in potency and quality, that the branded products will rise to the top and the Company intends to exploit all opportunities available to realize the full value of the Julian Marley brand and to attract other brands.

About JuJu Royal

Julian Marley conveys his message of legalization, freedom, and love through the JuJu Royal brand, a line of naturally produced medicinal herbs using the best solventless technology. One percent of proceeds are distributed for the benefit of veterans using cannabis through the Weed for Warriors Project. More information about the brand and various products can be obtained at www.jujuroyal.net. International Cannabrands is continuing to work with Julian Marley to identify and develop future strains of marijuana that meet Julian’s exacting standards. The Company is continuing to conduct research and development with certain origin genetics to produce additional signature Julian Marley strains for the JuJu Royal Premium Marijuana collection. The intent is to make these strains available to dispensaries and caregivers on a worldwide basis where it is legal.

International Cannabrands Contact:

Jeffrey Britz	CFN Media Contact:
Chairman & CEO	Frank Lane (206) 369-7050
1045 Lincoln Street, #106	flane@cannabisfn.com
Denver, Colorado 80203
201-394-7882 or jeffrey@jujuroyal.net
Media Inquiries: media@jujuroyal.net

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR THEIR REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward Looking Statements

This news release contains forward-looking statements relating to expectations about the benefits of an agreement between the Company and Cathedral City Care Collective for the distribution of its JuJu Royal products. These forward looking statements involve risks and uncertainties. Events or circumstances may cause actual results to differ materially from those anticipated as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company or the parties to the agreement. These include legal and regulatory changes, the impact of general economic, industry and market conditions; expectations regarding market demand for particular products and the dependence on new product development; the impact of product competition. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Management of the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

To view the associated document to this release, please click on the following link:
public://news_release_pdf/InternationalCanna03012018_0.pdf

To view the original release, please click here

Source: International Cannabrands Inc. (CSE:JUJU.A, OTC Bulletin Board:GEATF)

To follow International Cannabrands Inc. on your favorite social media platform or financial websites, please click on the icons below.

The post International Cannabrands Ltd. Announces Launch of Retail Strategy to distribute JuJu Royal™ Products appeared first on CannabisFN.

Future Farm Estimates $3,000,000 USD in Revenue in 2018 From 10-Acre Operating Greenhouse in Florida

Written by Ryan Allway on

Vancouver, British Columbia, March 01, 2018 (GLOBE NEWSWIRE) — Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce estimated 2018 projections on its 10-acre operating greenhouse. This 10-acre greenhouse in Apopka, Florida is located in a designated legal grow zone with close proximity to Orlando, which has a local population of almost 2.5 million and attracts over 62 million visitors annually. The greenhouse business will provide Future Farm with cash flow while serving as a major building block for the Company as it prepares to position itself in the emerging Florida cannabis market, estimated to climb to $1.6 billion in medical cannabis sales by 2020.

The Company plans to upgrade the nursery’s technology platform with new computers and software, a new phone system and fully implemented automated accounting, inventory management and order tracking systems. In addition, the Company plans to activate the online ordering platform, which to date has been non-functional, to penetrate higher margin markets such as direct to consumer wedding sales. Finally, the Company plans to initiate an online and social media marketing effort in part by employing the services of an ad agency.

As of July 2017, Florida had approximately 26,000 registered medical cannabis patients, and by October the number of registered medical cannabis patients surged to 38,000. It is anticipated that these numbers will likely continue to grow significantly over the next few years, due to the large number of retirees residing in Florida. It is expected that the Florida cannabis market will be only second in size to California, which in the last quarter of 2017 had 34 percent market share of legal pot sales. Colorado, Washington and Oregon had 41 percent share combined as of the same time period.

“We continue to execute on our planned strategy of building a portfolio of valuable, revenue-generating assets in the fastest growing cannabis and hemp markets in the country,” says William Gildea, Future Farm’s CEO and Chairman. “Our portfolio has grown quickly over the past year with assets acquired in Rhode Island, Maine, California and Puerto Rico, in addition to the acquisition of our Florida greenhouse and nursery.”

For further information, contact William Gildea, Director, at 617.834.9467.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, CEO & Chairman

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land. The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability. The Company also utilizes a leading cannabis oil extraction technology, which enables the Company to process 20lbs/hour of cannabis plant to yield approximately 908 grams/hour of oil.

The post Future Farm Estimates $3,000,000 USD in Revenue in 2018 From 10-Acre Operating Greenhouse in Florida appeared first on CannabisFN.

Revive Therapeutics and Ehave Enter Into Patient Research Data Collaboration Agreement for Medical Cannabis Liver Disease Program

Written by Ryan Allway on

TORONTO, March 01, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive“) (RVV.V) (RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, and Ehave, Inc. (“Ehave”) (EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, are pleased to announce that they have entered into a collaboration agreement to enable enhanced patient and clinical research data management for Revive’s research initiatives involving medical cannabis for the treatment of liver diseases.

The collaboration agreement will leverage Ehave’s core expertise in health informatics through its Ehave Connect platform. Revive will integrate the Ehave Connect solution of diagnostic and treatment tools with its ongoing research initiatives in liver disease to improve the lives of patients. Ehave Connect will collect and integrate patient data from clinical systems, licensed health surveys, and Ehave’s own patient- and clinician-reported outcome applications, empowering users with an end-to-end patient management solution, allowing for better treatment decisions across teams and disciplines while keeping patients informed and engaged throughout their healthcare journey.

“We are very excited with our collaboration with Ehave as it provides us with a foundation of employing next generation patient and clinical research data management solutions early on in the research and development phase of our liver disease program,” said Craig Leon, Chief Executive Officer of Revive. “Ehave’s Platform will support our research and clinical decisions and it will allow us to make objective, data-driven decisions throughout the course of our research and may provide unique insights to expand our initiatives with cannabinoids for the potential treatment of liver diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and fibrosis.”

“Our collaboration with Revive is an important step toward realizing Ehave’s broader goal of partnering with the healthcare community, and in particular companies advancing novel medical cannabis products, to facilitate clinical trials and patient management with a single easy-to-use, end-to-end data informatics platform,” stated Prateek Dwivedi, President and CEO of Ehave. “Not only will this collaboration help to streamline Revive’s research and clinical programs, but it also stands to further establish Ehave’s position as a leader in the health informatics space.”

About Ehave, Inc.

Ehave, Inc. (EHVVF) is empowering the mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave’s mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems (“MHS”), a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder (“ADHD”), through its collaboration with the Hospital for Sick Children (“SickKids”). Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with leading medical cannabis licensed producers. For more information, visit www.ehave.com.

About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. (TSX VENTURE:RVV)(RVVTF) is focused on the research, development and commercialization of novel therapies and technologies for the medical cannabis and cannabinoid-based pharmaceutical markets. Additional information on Revive is available at www.ReviveThera.com

Ehave, Inc. Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

Revive Therapeutics Ltd. Cautionary Note Regarding Forward-Looking Statements

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

This news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute “forward-looking information” that involves known and unknown risks and uncertainties, which are not comprised of historical facts, and most of which are beyond the control of Revive. Forward-looking statements include estimates and statements that describe Revive’s future plans, objectives or goals, including words to the effect that Revive or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “intends”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”, and similar expressions. Specifically, forward-looking statements in this news release include, without limitation, statements regarding: the granting of a patent for Bucillamine for the treatment of gout; the potential efficacy and commercial viability of Bucillamine for treatment of gout and Bucillamine for the treatment of Cystinuria; expansion of the Bucillamine clinical testing program; the Company’s drug research and development, and commercialization plans; the Company’s research, development and commercialization plans for plant-based therapies, including cannabinoids; the timing of operations; and estimates of market conditions. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events, performance, or achievements of Revive to differ materially from those anticipated or implied in such forward-looking statements. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. The Company believes that the expectations reflected in these forward-looking statements are reasonable, but there can be no assurance that actual results will meet management’s expectations. In formulating the forward-looking statements contained herein, management has assumed: that business and economic conditions affecting Revive will continue substantially in the ordinary course and will be favourable to Revive; that clinical testing results will justify commercialization of the Company’s drug candidates; that Revive will be able to obtain all requisite regulatory approvals to commercialize its drug candidates; that such approvals will be received on a timely basis; and, that Revive will be able to find suitable partners for development and commercialization of its drug repurposing candidates on favourable terms. Although these assumptions were considered reasonable by management at the time of preparation, they may prove to be incorrect and no assurance can be given that such events will occur in the disclosed time frames or at all.

Factors that may cause actual results to differ materially from those anticipated by these forward-looking statements include: uncertainties associated with obtaining regulatory approval to perform clinical trials and market products; the need to establish additional corporate collaborations, distribution or licensing arrangements; the Company’s ability to raise additional capital if and when necessary; intellectual property disputes; increased competition from pharmaceutical and biotechnology companies; changes in equity markets, inflation, and changes in exchange rates; and other factors as described in detail in Revive’s Management’s Discussion & Analysis for the period ended June 30, 2017 and Revive’s other public filings, all of which may be viewed on SEDAR (www.sedar.com). Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. Except as required by law, Revive disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Contact:

For Ehave, Inc.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
(212) 375-2664
jdrumm@tiberend.com

Janine McCargo (Media)
646-604-5150
jmccargo@tiberend.com

For Revive Therapeutics Ltd.
Craig Leon
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: (416) 272-5525
Email: craig@revivethera.com
Website: www.revivethera.com

The post Revive Therapeutics and Ehave Enter Into Patient Research Data Collaboration Agreement for Medical Cannabis Liver Disease Program appeared first on CannabisFN.

India Globalization Capital Partners with Parkinson’s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)

Written by Ryan Allway on

BETHESDA, Md., March 01, 2018 (GLOBE NEWSWIRE) — India Globalization Capital, Inc. (NYSE American:IGC) today announces that it has signed a Joint Development and Services Agreement with the prestigious Parkinson’s Institute and Clinical Center of Sunnyvale, California.

The Parkinson’s Institute and Clinical Center will work with IGC in identifying new clinical end points for Parkinson’s disease and movement disorders that could be used to determine if natural products can help with the debilitating symptoms in Parkinson’s patients. The Parkinson’s Institute and Clinical Center will assist in designing trials and creating protocols including a schedule of assessment, exclusion criteria, and registration with the National Institute of Health (NIH) and other agencies as required using IGC’s cannabis extracted products. Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center, a renowned expert in neuroscience & neurodegeneration, will be the lead on these initiatives.

“We believe that cannabis-based compounds can become part of the solution to treat the symptoms of challenging and progressive medical conditions such as Parkinson’s disease and movement disorders. Dr. Barlow and the Parkinson’s Institute and Clinical Center are highly respected in the field and we look forward to working together to bring cannabis-based options to those afflicted by this difficult diagnosis,” stated Ram Mukunda, CEO of IGC.

“We feel very fortunate to collaborate with IGC in a rigorous research approach to determine whether holistic cannabis products can alleviate the symptoms of Parkinson’s and movement disorders,” says Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center. “This is an opportunity for the Parkinson’s Institute and Clinical Center to participate in this scientific clinical study to help Parkinson’s patients worldwide.”

About Parkinson’s Institute and Clinical Center:
The Parkinson’s Institute and Clinical Center is at the forefront of patient care and therapy development. We are the nation’s only Institute that provides patient care, basic science research, and clinical research in one integrated model. Our unique freestanding organization directly connects research to patient care – from the “bench to bedside.” For 30 years, our team of epidemiologists, physicians, scientists, and therapists, have been at the forefront of every clinical and scientific discovery in the field of Parkinson’s research.

Since our inception, patients have come from 38 states and many foreign countries for their care. We have managed more than 135 clinical research trials, medically evaluating more than 95 different drugs and therapies for Parkinson’s. The result: our Institute has been directly involved in bringing every Parkinson’s drug currently available to the market. The Institute is at the forefront of discovering and developing the latest, most innovative treatments and therapies for people living with Parkinson’s. For more information visit www.thepi.org.

About IGC:
IGC has two lines of business, a legacy infrastructure and commodity trading business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). The Company is based in Maryland, USA.

For more information please visit www.igcinc.us ; www.igcpharma.com
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Contact:
Claudia Grimaldi
301-983-0998

The post India Globalization Capital Partners with Parkinson’s Institute and Clinical Center to Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD) appeared first on CannabisFN.

THC BioMed Engages CFN Media to Develop New Investor Audience

Written by Ryan Allway on Feb 28, 2018

SEATTLE, WA — March 1, 2018 — CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that THC BioMed International Ltd. (CSE: THC) (OTC: THCBF) (FRA: TFHD) has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on March 1st, 2018.

“We’re excited to be working with THC BioMed, a licensed producer of medical cannabis in Canada and the country’s largest supplier of cannabis genetics”, said Frank Lane, President of CFN Media. “The company continues to expand its footprint, announcing in February, that it signed a letter of intent to purchase a farm in the Niagara region of Ontario with 70,000 sq. ft. in the greenhouses, as well as irrigation and other equipment that’s ready to grow medical marijuana.”

“Our recent DTC eligibility ,GMP certification and moves to penetrate the International Cannabis Market necessitates the need to attract a wider Investor Audience “.”We look forward to working with CFN Media to develop our investor and market visibility while strengthening shareholder Value “Commented John Miller President and CEO of THC BioMed International

CFN Media will leverage its powerful content platform and extensive reach into mainstream and cannabis-focused investor audiences and media across North America to attract high-quality investors to THC BioMed International Ltd. while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading agency and financial media network dedicated to the worldwide cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Private and public marijuana companies in the US and Canada rely on CFN Media to succeed in the capital markets.

About THC BioMed International Ltd.

THC BioMed International Ltd. is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. The company is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well positioned to be in the forefront of this rapidly growing industry.

Visit the company’s website at www.thcbiomed.com.

Frank Lane

206-369-7050

flane@cannabisfn.com

The post THC BioMed Engages CFN Media to Develop New Investor Audience appeared first on CannabisFN.

Evolve Formulas Expands Product Line with Return of 5ml NanoSerum™ Pen

Written by Ryan Allway on

20 Dose-Dispenser Provides Discrete and Hassle-Free Option for Evolve Customers

DENVER (Feb 28, 2018) – Back by popular demand, the 5ml Transdermal NanoSerum™ pen is now available in more than 90 dispensaries throughout Colorado. This compact product size contains 20 doses of NanoSerum™, each with 10mg of THC. The game-changing Evolve Formulas product immediately penetrates the skin following application to deliver direct-focused relief from pain, inflammation and anxiety.

NanoSerum™ is the only transdermal cannabis product offering a patent-pending delivery system for cannabis molecules which uses nanotechnology to transport THC directly into the bloodstream and to the CB1 and CB2 receptors of the endocannabinoid system, offering precise, measurable doses and rapid absorption. Using the NanoSphere Delivery System™’s industry-first technology, cannabinoid molecules are encapsulated in natural, nano-sized lipid spheres, enabling them to cross the skin barrier to the bloodstream and cells, increase bioavailability and bioactivity.

“Evolve Formulas is expanding its product line with adaptations and new innovations that meet consumer needs,” said David Sutton, COO and President of Evolve Formulas. “Our product pipeline brings next-generation technology to cannabis consumers, providing fast-acting, measurable doses of cannabinoids that go directly to where they are needed, no ingestion or inhalation required.”

Unlike oral ingestion or inhalation, use of Transdermal NanoSerum™ offers results within ten minutes, with cannabis reaching the bloodstream in less than three minutes. The technology also provides consistent, measurable, standardized dosing and has advanced non-invasive, user-friendly administration in the cannabis and pharmaceutical industries, while also decreasing the adverse effects of cannabis.

NanoSerum™ is now available in 5ml and 10ml pen sizes in select medical and recreational dispensaries throughout Colorado. For a full list of store locations or more information, please visit https://www.evolveformulas.com/store-locator/ . The NanoSerum™ formula is 100 percent natural and 100 percent free of contaminants, made from natural biocompatible, biodegradable non-toxic materials.

For more information or to schedule an interview, please contact Emily Kielthy at media@nanospherehealth.com or 646-695-7045.

About Evolve Formulas

The post Evolve Formulas Expands Product Line with Return of 5ml NanoSerum™ Pen appeared first on CannabisFN.

ABcann Global Completes $70 Million Bought Deal Financing and $4.8 Million Exercise of Underwriters’ Over-Allotment Option

Written by Ryan Allway on

ABcann Global Corporation (TSXV:ABCN) (“ABcann” or the “Company”) is pleased to announce that it has closed its bought deal financing, as previously announced on January 29, 2018, of: (i) 11,500,000 units (each, a “Unit”) of the Company at a price of $3.50 per Unit, for aggregate gross proceeds of $40,250,000 (the “Unit Offering”); and (ii) 30,000 6.0% unsecured convertible debentures (each, a “Convertible Debenture”) of the Company at a price of $1,000 per Convertible Debenture, for aggregate gross proceeds of $30,000,000 (the “Debenture Offering” and collectively with the Unit Offering, the “Offering”). The Offering was conducted by a syndicate of underwriters led by Canaccord Genuity Corp. and Eight Capital and including GMP Securities L.P. and PI Financial Corp. (collectively, the “Underwriters”). In addition, the Offering included 862,500 Warrants (defined below) and 4,500 Convertible Debentures sold pursuant to the exercise of the Underwriters’ over-allotment option, for additional aggregate gross proceeds of $4,793,250.

“Completion of the Offering further increases our cash position to over $135 million and will allow us to pursue multiple opportunities and execute our strategic vision,” stated Barry Fishman, ABcann’s Chief Executive Officer.

The Units and the Convertible Debentures were offered by way of a short form prospectus (the “Prospectus”) in all provinces of Canada except Quebec. The net proceeds of the Offering will be used for the expansion of the Company’s Vanluven facility, construction and development at the Company’s Kimmett facility, corporate development, product development and general working capital.

The Prospectus also qualified the distribution of 20,000,000 common shares of the Company (each, a “Common Share”) issuable on conversion of the $30,000,000 of aggregate principal amount of 7.0% unsecured convertible debentures of the Company issued on December 21, 2017.

The Unit Offering

Each Unit is comprised of one common share (each a “Unit Share”) of the Company and one‐half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one additional Common Share (each, a “Warrant Share”) of the Company at an exercise price of $4.25 per Warrant Share, subject to adjustment in certain circumstances, until February 28, 2020. The Warrants were issued pursuant to the terms of a warrant indenture entered into between the Company and TSX Trust Company, as warrant agent. In the event that the Common Shares have a daily volume weighted average trading price of $7.00 or higher on the TSX Venture Exchange (the “TSXV”) for a period of 15 trading days, the Company shall be entitled to accelerate the exercise period of the Warrants to a period ending not less than 30 days from the date written notice of acceleration is provided to Warrant holders.

The Debenture Offering

The Convertible Debentures mature on February 28, 2021 (the “Maturity Date”) and the outstanding principal of the Convertible Debentures bears interest (the “Debenture Interest”) at 6.0% per annum, payable semi-annually in arrears on June 30 and December 31 in each year, commencing on June 30, 2018. The Convertible Debentures have been issued pursuant to the terms of a debenture indenture entered into between the Company and TSX Trust Company, as debenture trustee. Each Convertible Debenture is convertible into Common Shares (each, a “Conversion Share”) at the option of the holder at any time prior to the close of business on the earlier of the last business day immediately preceding the Maturity Date at a conversion price of $4.00 per Conversion Share, subject to adjustment in certain circumstances.

About ABcann:

ABcann holds production and sales licenses from Health Canada. Its flagship facility in Napanee, Ontario contains proprietary plant-growing technology, centred on its specially designed, environmentally-controlled growing chambers. This approach results in the production of pharmaceutical-grade cannabis products.

The Company is expanding its cultivation capacity and pursuing partnerships and product development opportunities domestically, as well as in select international markets, such as Germany, Australia and Israel.

The post ABcann Global Completes $70 Million Bought Deal Financing and $4.8 Million Exercise of Underwriters’ Over-Allotment Option appeared first on CannabisFN.

Choom™ Appoints Chris Gagan as SVP Marketing

Written by Ryan Allway on

VANCOUVER, Feb. 28, 2018 /CNW/ – Choom™ (CSE: CHOO; OTCQB: CHOOF) today announced the appointment of Chris Gagan as Senior Vice President of Marketing to lead its brand strategy and execution. Reporting to Chief Executive Officer, Chris Bogart, Mr. Gagan will provide overall leadership and guidance to the marketing function and all its specialities, as well as provide insight into the overall corporate strategy.

Choom Holdings Inc. (CNW Group/Choom Holdings Inc.)

Mr. Gagan brings over 20 years of marketing expertise and lifestyle brand development, product development, and retail expertise across a variety of wholesale and retail channels, most recently with Canada’s largest national retailer of sporting goods FGL Sports, where he led the design and development team for their exclusive brands division.

“We’re excited to bring Chris on to our leadership team,” said Mr. Bogart. “His experience with lifestyle marketing, design and sports branding with Fox Racing and Sugoi Performance Apparel will be important in positioning Choom^TMas a leading lifestyle brand in Canada. In addition, his knowledge of retail merchandising will help accelerate and solidify Choom’s position within the recreation cannabis sector in Canada.”

As part of the senior leadership team, Mr. Gagan will be responsible for the development and execution of the Choom™ brand and retail marketing strategy. Mr. Gagan will also be integral to driving product marketing and market research for Choom™ as it prepares for the upcoming legalization of cannabis for recreational use across Canada.

SAY HELLO TO CHOOM^TMChoom™ was inspired by the Choom Gang; a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom“. Now, after four decades, Choom^TM is bringing the spirit of Hawaii to the Okanagan and Canada. We’re planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb. Choom™ will provide an amazing experience for customers, and bring style, sophistication and fun to the cannabis market through our Choom™ stores.

“Chris Bogart”
President & CEO

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE Choom Holdings Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/February2018/28/c3105.html

Choom Holdings Inc.,Chris Bogart, President & CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.caCopyright CNW Group 2018

Source: Canada Newswire (February 28, 2018 – 7:30 AM EST)

News by QuoteMedia

The post Choom™ Appoints Chris Gagan as SVP Marketing appeared first on CannabisFN.

The Hydroponics Company Receives Import Permits in Australia

Written by Ryan Allway on

The Hydroponics Company Limited (ASX:THC) (“THC”) is pleased to advise that the Drug Control Section of the Department of Health has granted THC permission to commence importing medicinal cannabis products from its European partner, Endoca. The Endoca product range includes;

15% RAW CBD oil, 10ml
15% Heated/decarb CBD oil, 10ml
3% RAW CBD oil, 10ml
3% Heated/decarb CBD oil, 10ml

The approval by the Drug Control Section of the Department of Health is a significant step forward which will enable THC to commercialise its distribution agreement with Endoca by importing medicinal cannabis products into Australia. Endoca is a global leader in the supply of product sourced from Hemp plants, with a focus upon delivery of the highest quality CBD products. These products have been used successfully in Europe in the treatment of Epilepsy and associated neurological disorders. THC will make these products available through both the National Access Clinics that it will be establishing, as well as direct order for patients on the Special Access Scheme or working with an Approved Prescriber.

THC confirms NAC Canada’s Systems Implementation Manager, who arrives in Sydney this week on a 6-month secondment, will transfer intellectual property from NAC Canada in the form of operational support to facilitate an adapted clinics model aligned to the Australian clinical and regulatory environment. Access to treating key opinion leaders in Canada will facilitate informed prescribing through the development of treatment protocols based on available product ranges.

Commenting on the approval, THCs Chief Executive Officer, David Radford, said: “With the approval to commence importing Endoca’s highest quality product range, THC is well placed to begin commercialisation and we look forward to developing this long term relationship”

In addition, BOL Pharma Limited (BOL), a leading Israeli medicinal cannabis company, confirms supply of investigational medicinal product in the form of a proprietary sublingual tablet containing THC and CBD, to further research into the potential benefits of medicinal cannabis in Tourette’s Syndrome. An Australian-first study of medicinal cannabis as a treatment for the debilitating neurological condition Tourette syndrome is to be conducted by Wesley Medical Research.

Canndeo Limited, a wholly owned Australian subsidiary of THC, will act on behalf of BOL to facilitate provision of the investigational product in support of the clinical trial conducted by Wesley Medical Research. The trial is expected to commence Q2 2018. Wesley Medical Research Institute neuropsychiatrist Philip Mosley said they will trial the medicinal cannabis product in 24 adults with severe Tourette syndrome. Dr Mosley added “many doctors were unwilling to prescribe medicinal cannabis because there’s very limited evidence for it for most conditions. I’m hoping that this trial will enable doctors to prescribe with more confidence if they have a patient with Tourette syndrome.”

The Israeli government recently announced approval for the commercial export of medicinal cannabis is still pending, however, export of products for international research purposes is permissible. This will enable BOL and Canndeo to explore further targeted research in Australia

The post The Hydroponics Company Receives Import Permits in Australia appeared first on CannabisFN.

Naturally Splendid Highlights Protein Industries Canada Supercluster Government Funding

Written by Ryan Allway on Feb 27, 2018

Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSX-V:NSP) (OTCQB:NSPDF) (Frankfurt:50N) is pleased to learn that Protein Industries Canada (PIC) has received funding from Canada’s federal department of Innovation, Science and Economic Development. PIC, as one of the successful industry “Superclusters”, will receive a portion of the $950 million allocated to this important, innovative initiative.

Naturally Splendid is pleased to be one of the core supporters of this program which will potentially open the doors for collaborative partnerships in ground breaking development of proprietary ingredients such as NSE’s HempOmega™ and protein isolate. Based on our company’s initial commitment over the next five years, NSE could be eligible for matching funding of up to $2.5 million. By leveraging that with funds and technologies from other PIC participants, the impact to our company and our industry could be magnified significantly.

Naturally Splendid Director and Canadian Hemp Trade Alliance President Mr. Russ Crawford states, “The selection of the Protein Supercluster by the federal government represents a huge growth opportunity for western Canadian agricultures under developed value-added sector. The Canadian Hemp Trade Alliance and Naturally Splendid Enterprises are very excited about the implications for the hemp industry, as 100% of our hemp production is already processed prior to export. The value-added potential and market growth this funding represents will catapult the hemp industry due to its comparatively high-quality ingredient profile”

Naturally Splendid CEO Mr. Douglas Mason states, “Naturally Splendid has positioned our company to be an ingredient supplier of plant-based protein and omega products including cannabis extracts such as CBD. We are on the leading edge of scientific development of food fractionation and ingredient optimization and look forward to expanding the development of our Intellectual Property through this program. Our company is a very good fit with the PIC initiative in the area of Process Technology Innovation. The success of the PIC supercluster application, and our small role in its execution, could mean significant growth for our company. By having a diversified strategic plan that includes opportunities outside the cannabis space, we in fact create more opportunities for the Company while waiting for cannabis regulations to positively evolve in Canada and globally.”

“The target markets presented in the PIC application align perfectly with NSE’s product development strategy,” states NSE VP of Product Development, Bryan Carson. “Our product mix includes the four key markets of Food & Beverages, Infant Formulations, Personal Care & Cosmetics and Animal Feed. In addition, we are targeting Personal Health and Wellness and Senior’s Formulations.”

The Protein Industry Canada website states, “Plant-based protein is a $13 billion market opportunity. Outcomes from this cluster will be a new range of plant-derived foods, ingredients and feedstuffs of superior quality, commanding market premiums.

PIC projects the global population to reach 9.8 billion people by 2050 with the largest growth in the middle class. This growing sector of more affluent consumers are looking for more plant-based protein in their diet. They also want sustainable and environmentally friendly sources of food.

The development of a “Silicon Valley for plant-based protein” in western Canada represents the potential for $40 billion in investment, 40,000 direct jobs and 120,000 indirect jobs.

About Protein Industries Canada

Protein Industries Canada (PIC) is an industry-led value chain consortium of small- to large-sized enterprises involved in food and food ingredient manufacturing, agriculture and food-related services, research and development, technology, economic development, finance and investment, education and training.

PIC is a not-for-profit corporation guided by a board comprising industry leaders and supported by Ag-West Bio and regional partners.

Vision: “To position Canada globally as a leading source of high-quality plant protein and plant-based co-products, developed in a carbon neutral production environment, while substantially contributing to Canada’s economic growth and international trade balance.”

Mission: “To mobilize Canada’s innovation and commercial cluster to collaborate in support of industry driven market priorities and needs.”

About Naturally Splendid Enterprises Ltd.

The post Naturally Splendid Highlights Protein Industries Canada Supercluster Government Funding appeared first on CannabisFN.

Lexaria Enters Licensing Agreement with Cannabis Edibles Infusion Company

Written by Ryan Allway on

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the “Agreement”) with Los Angeles-based, privately-held Biolog, Inc. (“Biolog”) whereby Lexaria is providing its patented DehydraTECHTM technology to empower a unique set of next-generation food and beverage cannabis infusion products to be sold in the United States.

Biolog, Inc. has separately acquired rights to patented technologies for a unique line of manufactured dissolvable infusion products designed for ease of use and precise per-unit ingredient dosing. Biolog intends to launch new products of this type to deliver DehydraTECHTM enabled CBD from hemp and/or vitamins in products available nationwide. Biolog will also launch new DehydraTECHTM enabled products in those states where it is permissible to do so delivering cannabinoids from cannabis. All product lines will offer superior palatability and bioabsorption, as well as fast action powered by DehyrdaTECHTM.

Biolog has acquired 5-year exclusive rights to use Lexaria’s DehydraTECHTM technology for these particular applications within the United States for an undisclosed sum and a royalty on revenue generated on products sold utilizing DehyrdaTECHTM.

“The versatility of Lexaria’s DehyrdaTECHTM technology is witnessed through its adoption to deliver vitamins in a nationally-available consumer product, or cannabinoids in many U.S. states,” said Chief Executive Officer Chris Bunka. “Biolog’s products are a unique and novel method to deliver precisely measured amounts of active ingredients thoroughly infused into foods and beverages of virtually all kinds and we welcome Biolog to our growing family of technology innovators.”

Craig Machado, CEO of Biolog commented, “Lexaria’s technologies apply very well to our product offerings and we could not be more excited to be soon offering Powered by Lexaria products to the marketplace. We plan to provide more information about our upcoming products, which will allow processors and consumers to turn almost any food or beverage into a cannabis edible, in the near future as we get closer to formal product launch.”
Lexaria’s patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredient (“API”) substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria’s patented technology. Lexaria’s long term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.

About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com

About Biolog, Inc.
Biolog, Inc. is a privately held company located in Los Angeles specializing in cannabis infusion technology for food and beverages. Biolog has gained access, via various licensing agreements, to what it believes is some of the most important intellectual property in the legal cannabis edibles marketplace. Biolog has integrated this IP into a unique set of products that enable consumers and cannabis processors to turn virtually any food or beverage into a cannabis edible. The Company’s business model is to both directly manufacture cannabis infusion products, where legal, and to license its technologies to legal licensed third parties that will then utilize the cannabis infusion technologies to create cannabis containing foods and beverages.

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook http://tinyurl.com/y8vzcaam

FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com

The post Lexaria Enters Licensing Agreement with Cannabis Edibles Infusion Company appeared first on CannabisFN.

Hiku Brands Expands To Jamaica Through Strategic Alliance

Written by Ryan Allway on

TORONTO, Feb. 27, 2018 /CNW/ – Hiku Brands Company Ltd. (“Hiku” or the “Company”) (CSE: HIKU), Canada’s first vertically-integrated cannabis brand house, is pleased to announce that it has entered into a letter of intent (“LOI”) with Kaya Inc. (“Kaya”), the first licensed medical cannabis producer and dispensary operator in Jamaica, to launch a strategic alliance (“Strategic Alliance”) to pursue medical and adult-use cannabis branding, genetics, and retail opportunities in Jamaica and Canada.

Under the LOI, Hiku intends to make a strategic investment in Kaya to acquire up to 10% ownership on a fully diluted basis, enter into mutual licensing agreements to leverage Hiku’s brands in Jamaica and Kaya’s brand in Canada, work together to explore import and export opportunities for cannabis genetics, and develop co-branded retail stores and cannabis lounges in the Caribbean. The Strategic Alliance brings Hiku’s award winning cannabis brands and experiential retail offering to Jamaica and Jamaican cannabis consumers while providing Hiku the opportunity to share Kaya’s renowned cannabis genetics and top-tier, authentic Jamaican cannabis brand with Canadian cannabis market.

“This is an incredible opportunity for Hiku to tap into Jamaica’s world-renowned cannabis community and take our retail and branding expertise global”, said Alan Gertner, CEO of Hiku. “We’re excited to start working with the Kaya team and have been thoroughly impressed by their knowledge and passion. The Hiku team is excited to share in Kaya’s vision to provide an authentic-to-Jamaica cannabis retail experience, properly showcasing the amazing cannabis genetics produced by their sister-company, Ganja Labs. Jamaica has such a deep and rich history with cannabis and we are fortunate to be able to participate in and learn from that history.”

Bali Vaswani, Chairman and Chief Ganja Officer of Kaya, said “we are very excited to leverage the expertise of Hiku. As proven retailers with a strong operational foundation, we have found the perfect partners. Hiku is a world class brand builder and we are extremely pleased to bring their portfolio of brands, including Tokyo Smoke, DOJA and Van der Pop, to consumers alongside our local Jamaican brands.”

Hiku intends to enter into a subscription agreement with Kaya whereby Hiku will make an initial investment of $250,000, and intends to make a secondary investment concurrent with an equity financing by Kaya that would bring Hiku’s total ownership to 10% on a fully diluted basis post-financing.

Kaya and Hiku will work with the Cannabis Licensing Authority (“CLA”) in Jamaica to ensure compliance with the CLA’s international ownership framework.

* To the best of the company’s knowledge

About Hiku

Hiku is focused on building a portfolio of iconic, engaging cannabis brands, immersive retail experiences DOJA and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA’s ACMPR licensed grow, and Van der Pop’s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

DOJA Cannabis, Hiku’s wholly-owned subsidiary, is a federally licensed producer of craft cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”). DOJA owns and operates two production facilities in the heart of British Columbia’s Okanagan Valley. The Company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.
About Kaya

Kaya is the first medical cannabis brand and legal vertically integrated cannabis producer from the Caribbean. Kaya has been on the forefront of medical Ganja research with Jamaica’s University of Technology since 2015, where it was issued one of the original two medical cannabis research licenses by the Government. Kaya is also amongst the first cohort of licensees under Jamaica’s new CLA framework, issued in 2017. Through Kaya Farms, Everything Oily, Kaya Herbhouse, and Kaya Cafe, Kaya is able to cultivate, process, distribute, and retail medical cannabis to both tourists and Jamaicans alike. Kaya’s goal is to make Jamaica the flagship of the global wellness tourism industry and become the new symbol of the island’s roots and lifestyle.
Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include the Company’s intention to enter into a license agreement with Kaya, its intention to explore import and export opportunities with Kaya, its intention to develop co-branded retail stores with Kaya and its intention to enter into one or more subscription agreements to invest in Kaya and the terms of such investment. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

SOURCE HIKU Brands Company Ltd.

For further information: Abigail Van Den Broek, abby@abigailv.ca, 416-799-8510 or visit HIKU’s website at www.hiku.com.

The post Hiku Brands Expands To Jamaica Through Strategic Alliance appeared first on CannabisFN.